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ENGLISH SUMMARY 
Diabetes mellitus represents a major and growing public health problem, which is 
partly due to the diabetes related burden of cardiovascular disease.  Hence, a continued 
focus on cardiovascular disease prevention is needed and risk stratification in patients 
with diabetes is an important priority in the management of diabetes-related morbidity 
and mortality.   
The aim of this thesis was to contribute to the identification of new potential 
prognostic factors for cardiovascular disease among patients with diabetes. 
Specifically, we aimed to investigate the prognostic influence of diabetes type and 
glycaemic status in patients with diabetes and atrial fibrillation, and to investigate the 
prognostic influence of albuminuria in a general cohort of type 2 diabetes patients.  
The studies of this dissertation was based on data from Danish national registries. In 
study I, we found that the type of diabetes was generally not associated with a higher 
risk of ischemic stroke. However, in a subgroup of patients below 65 years, type 2 
diabetes was associated with a higher risk of ischaemic stroke.  In study II, we found 
that increasing levels of glycaemic status were associated with an increased risk of 
ischaemic stroke in patients with a shorter duration of diabetes but not in patients with 
a longer duration of diabetes. In study III, we found that micro- and macroalbuminuria 
were associated with a higher risk of incident ischaemic stroke and myocardial 
infarction in patients with type 2 diabetes. 
The studies of this dissertation have contributed to the identification of a number of 
risk factors for ischaemic stroke and myocardial infarction both in a general cohort of 
patients with diabetes and in patients with diabetes and concomitant atrial fibrillation. 
Identifying high- and low-risk subgroups provides basis for evidence-based clinical 
risk stratification that may serve as a valuable clinical tool in aiding clinical 
counselling of patients and guiding treatment decisions.    
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DANSK RESUME 
Diabetes er en hyppigt forekommende sygdom, der udgør et voksende folkesundheds 
problem, idet der medfølger en stor byrde af kardiovaskulær sygdom. Derfor er der 
fortsat et behov for fokus på forebyggelse af kardiovaskulær sygdom blandt patienter 
med diabetes. Anvendelse af risikostratificering af patienter med diabetes er et vigtigt 
redskab i håndteringen af diabetesrelateret morbiditet og mortalitet.     
Det overordnede formål med denne afhandling var, at identificere potentielle 
prognostiske faktorer for udviklingen af kardiovaskulær sygdom blandt patienter med 
diabetes.  De specifikke formål var at undersøge om risikoen for iskæmisk apopleksi 
er associeret med typen af diabetes og blodsukkerniveauet blandt patienter med 
diabetes og atrieflimren, samt at undersøge om risikoen for iskæmisk apopleksi og 
akut myokardieinfarkt er associeret med albuminudskillelsen i urinen iblandt patienter 
med diabetes.   
Studierne i denne afhandling er baseret på data fra danske nationale registre. I studie 
I fandt vi, at typen af diabetes overordnet set ikke var associeret med risikoen for 
iskæmisk apopleksi. Dog var det blandt patienter under 65 år en betydeligt større 
risiko forbundet med at have type 2 diabetes sammenlignet med type 1 diabetes. I 
studie II fandt vi, at stigende blodsukkerniveauer var forbundet med en betydeligt 
højere risiko for at udvikle iskæmisk apopleksi blandt patienter med kortere varighed 
af diabetes, hvorimod der blandt patienter med længere varighed af diabetes ikke var 
nogen sammenhæng mellem blodsukkerniveauet og risikoen for iskæmisk apopleksi. 
I studie III fandt vi, at stigende niveauer af albuminuri var forbundet med en højere 
risiko for både iskæmisk apopleksi og akut myokardieinfarkt blandt patienter med 
diabetes. 
Studierne i denne afhandling har bidraget til at identificere risikofaktorer for iskæmisk 
apopleksi og myokardieinfarkt blandt patienter med diabetes. Identificering af høj- og 
lavrisikogrupper blandt patienter med diabetes kan danne grundlag for evidensbaseret 
risikostratificering, som kan anvendes som et klinisk redskab til at rådgive patienter 
og til at træffe behandlingsmæssige beslutninger i den kliniske hverdag.  
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CHAPTER 1. INTRODUCTION  
Diabetes mellitus, commonly referred to as diabetes, is a group of metabolic disorders 
characterized by abnormally increased concentrations of glucose in the blood over a 
prolonged period of time. The overall prevalence of diabetes is reaching pandemic 
proportions, affecting more than 450 million people worldwide and 260,000 people 
in Denmark alone.1,2 The global prevalence of diabetes in adults has been increasing 
over recent decades and is expected to continue to rise in upcoming years.2–4  
Diabetes can be divided into several subtypes, whereof the vast majority of patients 
fall into two pathogenetic categories; type 1 and type 2 diabetes.5 With type 2 diabetes 
accounting for about 80% of all diabetes cases and type 1 diabetes accounting for 
about 10%. Type 2 diabetes is a metabolic disorder characterized by impaired insulin 
secretion and insulin resistance. The pathophysiological changes in type 2 diabetes 
include dysfunction of the insulin-producing β-cells in the pancreas, inadequate 
sensitivity of the body cells to the action of the insulin produced, and chronic 
inflammation.6 Type 2 diabetes is a multifactorial disease involving both genetic and 
lifestyle factors,7 with adiposity being the single most important risk factor for the 
development of type 2 diabetes.8 However, physical inactivity and genetic 
components affecting the development of obesity, insulin secretion, and insulin 
resistance also play important roles.9 Type 2 diabetes usually develops during 
adulthood, but a rise in the incidence of Type 2 diabetes in children and adolescents 
has been observed.10 Type 1 diabetes is an autoimmune chronic condition 
characterized by insulin deficiency due to destruction of insulin-producing β-cells in 
the pancreas.11 The process usually progresses over months to years during which the 
subject is asymptomatic. Type 1 diabetes develops during childhood and adolescents 
and may be triggered by environmental agents in genetically susceptible individuals.11  
People with diabetes have an increased risk of developing serious life-threatening 
health problems resulting in a reduced quality of life, increased mortality, and higher 
medical care costs.12–15 Persistently high blood glucose levels cause generalized 
vascular damage that affect nearly all blood vessel types and sizes, which leads to an 
increased risk of both microvascular complications, such as retinopathy, nephropathy, 
and neuropathy and macrovascular complications including coronary artery disease, 
peripheral arterial disease, and ischaemic stroke.16–19 Adults with diabetes have a two- 
to threefold increased risk of myocardial infarction and ischaemic stroke compared to 
adults without diabetes20 and two‐thirds of deaths in patients with diabetes are related 
to cardiovascular disease.21 Furthermore, the severity of diabetes mellitus, determined 
by disease duration, worse glycaemic control, or requirement for insulin treatment, 
has been associated with cardiovascular disease development.22 Not only, is diabetes 
associated with higher risk of cardiovascular disease, worse outcomes after 
myocardial infarction and ischaemic stroke have been observed in patients with 
diabetes compared to patients without diabetes.23–29  
DIABETES MELLITUS AND CARDIOVASCULAR DISEASE 
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The underlying pathophysiological mechanisms explaining this observed excess risk 
are complex. Insulin resistance and hyperglycaemia plays a pivotal role in the 
accelerated atherosclerotic process in diabetes.  Furthermore, chronic low-grade 
inflammation, primary haemostasis changes, increased levels of clotting factors, 
impaired fibrinolysis, and enhanced oxidative stress may be mediators of the 
prothrombotic state observed in diabetes.30,31  
Even though patients with diabetes have a two- to threefold increased risk of 
cardiovascular morbidity and mortality compared to individuals without diabetes,16–
19 diabetes is no longer considered a coronary risk equivalent.32 In fact, several studies 
suggest that a considerable part of patients are in a lower cardiovascular risk 
category.33,34 Hence, international guidelines now recommend cardiovascular risk 
stratification for patients with diabetes in order to determine the intensity of 
prevention strategies.35–37  
Prevention of cardiovascular disease in patients with type 2 diabetes can include 
antiplatelet treatment and management of abnormalities in blood glucose, lipids, and 
blood pressure. Generally these preventive strategies are divided into primary 
prevention and secondary prevention, applying to patients without cardiovascular 
disease and with cardiovascular disease, respectively. The essential difference in 
primary and secondary prevention is differences in treatment thresholds for lipid 
lowering and the recommendation regarding antiplatelet treatment. Intensified lipid 
lowering and antiplatelet treatment are generally recommended in secondary 
prevention. These recommendations are supported by several randomized controlled 
trials that have shown a net benefit of antiplatelet treatment and intensified lipid 
lowering in patients with type 2 diabetes and established cardiovascular disease.38–46 
More uncertainty about the intensity of treatment exists in treatment guidelines for 
primary prevention of cardiovascular disease in patients with diabetes as randomized 
controlled trials have not shown an overall net benefit of intensified lipid lowering 
and antiplatelet treatment in patients with diabetes but without cardiovascular 
disease.35,36 Guidelines from both the European Society of cardiology (ESC) and the 
American Diabetes Association (ADA) state that assessing the risk of a first-time 
atherosclerotic cardiovascular event can aid the clinician in discriminating higher- 
from lower-risk patients and thereby make informed decisions about the intensity of 
preventive treatment.35,47 
Identifying potential prognostic factors for the development of cardiovascular disease 
in patients with diabetes may optimize risk stratification. This may allow us to identify 
high-risk subgroups in the diabetes population who would benefit from intensive 
preventive treatment, while avoiding overtreatment in lower risk cases.  
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The link between diabetes and stroke is complex, for instance, diabetes has been 
linked to ischaemic stroke but not to haemorrhagic stroke.48 To add to the complexity, 
ischaemic stroke is an umbrella term covering several subtypes of ischaemic stroke, 
e.g. atherosclerotic and cardioembolic strokes. Whereas the link between diabetes and 
atherosclerotic strokes are well established, the role of diabetes as an independent risk 
factor for cardioembolic stroke is more conflicting.49,50   
Cardioembolic stroke is often caused by atrial fibrillation and approximately 20% of 
all ischaemic strokes are estimated to be attributed to atrial fibrillation.4 Atrial 
fibrillation is a supraventricular arrhythmia characterised by disorganized electrical 
activity in the atria causing an irregular and often rapid heart rhythm. Atrial fibrillation 
is the most common sustained arrhythmia affecting more than 33.5 million people 
worldwide.51 The prevalence of atrial fibrillation more or less doubles with each 
decade of age, rising to almost 9% at 80-90 years.52 It is expected that the prevalence 
will increase in upcoming years, primarily due to the increased aging of the population 
but also due to an increase in established risk factors for atrial fibrillation among 
others diabetes.53,54 In fact, it has been estimated that people with diabetes have an 
approximately 40% greater risk of incident atrial fibrillation compared with people 
without diabetes.55 Not only is diabetes associated with increased risk of developing 
atrial fibrillation, diabetes has also been associated with a higher risk of ischaemic 
stroke in patients who have already developed atrial fibrillation56–58 Hence, diabetes 
is incorporated in the guideline-recommended thromboembolic risk stratification tool, 
the CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥75, diabetes, 
ischaemic stroke/transient ischaemic attack, myocardial infarction/peripheral artery 
disease, age ≥65, and female sex).59 According to guidelines, anticoagulation 
treatment should be considered for men with a CHA2DS2-VASc score of 1 and women 
with a score of 2, balancing the expected stroke reduction, bleeding risk, and patient 
preference. Consequently, all patients with diabetes mellitus are hereby potential 
candidates for life-long anticoagulant treatment. This simplistic approach to stroke 
risk stratification neglects the diversity of the diabetes population. By exploring 
whether it is possible to identify prediction markers for thromboembolic events in 
patients with diabetes and atrial fibrillation, we can clarify if it is possible to identify 
subgroups of patients with different thromboembolic risk, which could lead to more 
differentiated treatment recommendations.  
 

17 
 
CHAPTER 2. AIMS AND HYPOTHESES 
The overall aim of this PhD project was to contribute to the identification of new 
potential prognostic factors for cardiovascular disease as well as potential therapeutic 
targets for cardiovascular risk reduction among patients with diabetes.  
Study I 
Aim: To examine whether type 1 and type 2 diabetes are associated with different 
risks of thromboembolism among patients with incident nonvalvular atrial fibrillation. 
Hypothesis: Type 2 diabetes is associated with a higher risk of thromboembolism than 
type 1 diabetes in patients with incident nonvalvular atrial fibrillation.    
Study II 
Aim: To examine the effect of glycaemic status as reflected by haemoglobin A1c 
(HbA1c) on the risk of thromboembolism in patients with atrial fibrillation and type 
2 diabetes; and to examine whether the effect of elevated HbA1c on the risk of 
thromboembolism was modified by the duration of diabetes. 
Hypothesis: Increasing levels of HbA1c is associated with a higher risk of 
thromboembolism in patients with atrial fibrillation and type 2 diabetes and the 
association between HbA1c and thromboembolism is modified by diabetes duration.   
Study III 
Aim: To examine the association between micro- and macroalbuminuria and incident 
ischaemic stroke, myocardial infarction, and all-cause mortality in a nationwide 
cohort study of patients with type 2 diabetes without prevalent atherosclerotic 
cardiovascular disease. 
Hypothesis: In patients with type 2 diabetes, micro- and macroalbuminuria are 
associated with a higher risk of incident ischaemic stroke, myocardial infarction, and 
all-cause mortality. 
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CHAPTER 3. METHODS 
 
The studies in this dissertation were cohort studies based on data from Danish 
nationwide registries. Our studies were based on historical data, mainly collected for 
administrative purposes; however, the studies were designed and analysed 
prospectively, thereby ensuring that disease under study occurred after the exposure 
of interest.  
 
Denmark has a long history of collecting information on vital status, 
immigration/emigration, redeemed prescriptions, and disease incidence in Danish 
administrative and clinical registries.60 By using a unique personal identification 
number (CPR-number), which is assigned to all residents in Denmark, it is possible 
to link data from the various registries to obtain individual level data.61 The registries 
contain data reflecting clinical practice and covers the entire population. This creates 
the possibility for large sample sizes and a high representativeness of the results.62 
Accordingly, the Danish registries have been extensively used for epidemiological 
research.62 
All studies in this dissertation are based on the Danish National Prescription 
Registry,63 the Danish National Patient Registry,64 and the Danish Civil Registration 
System.61 Moreover, study II and III are also based on data from the Danish Adult 
Diabetes Registry.65 The data was linked through Statistics Denmark. In the following 
section a concise description of the aforementioned registries is provided.  
The Danish Civil Registration System 
The Danish Civil Registration System was established in 1968. The registry holds 
information on date of birth, vital status, sex, and migration.61 Contemporary 
information on migration and vital status allows for long-term follow-up in 
nationwide cohort studies with accurate censoring at emigration or death.66  
The Danish National Patient Registry 
The Danish National Patient Registry is a nationwide hospital based registry that 
provides longitudinal registration of comprehensive administrative and clinical data.64 
Since 1977, information on all patients discharged from Danish non-psychiatric wards 
has been registered. Moreover, information from psychiatric wards, outpatient 
contacts, and emergency departments has been registered since 1995 and from private 
hospitals since 2003.62 For each patient contact the physician, discharging the patient, 
registers one primary diagnosis and optional secondary diagnoses. The diagnoses are 
DIABETES MELLITUS AND CARDIOVASCULAR DISEASE 
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classified according to the International Classification of Diseases (ICD). Originally 
the 8th revision of ICD was used and since 1994 the 10th revision has been used.62 The 
registry was used in all three studies to obtain information on the incidence of the 
study outcomes: ischaemic stroke, systemic embolism, and acute myocardial 
infarction. Moreover, information on the patients’ comorbidity was partly obtained 
from the Danish National Patient Registry.  
The Danish National Prescription Registry 
The Register of Medicinal Product Statistics was established in 1994 and collects 
individual-level data on all prescriptions redeemed by Danish residents in Danish 
pharmacies. Since 2003, these data were made available for researchers in an 
independent sub-registry named the Danish National Prescription Registry.63,67 The 
Registry holds information on all prescription drugs sold in Denmark since 1995. 
Nonetheless, information on over the counter drugs is only registered as aggregated 
data. For each redeemed prescription an electronic record is generated. The record 
includes the date of dispensing and the type and amount of the prescribed drug, coded 
according to the Anatomical Therapeutic Chemical (ATC) Classification System.63 In 
all studies, the Danish National Prescription Registry was used to identify the use of 
medication at inclusion and throughout the study. Furthermore, the registry was used 
in combination with the Danish National Patient Registry to define specific comorbid 
conditions. 
Danish Adult Diabetes Registry 
The Danish Adult Diabetes Registry is a nationwide quality database that collects data 
from annual diabetes care check-ups in outpatient clinics and in general practice. Data 
has been collected from outpatient clinics since 2004 whereas data from general 
practice has been reported to the registry since 2006.65 Among other things, 
information on date of diabetes mellitus diagnosis, HbA1c measurements, urinary 
albumin-to-creatinine ratio (UACR) or the urinary albumin excretion rate (UAE) 
measurements, smoking status, body mass index, blood pressure measurements, and 
lipid status is reported to the registry.12 Approximately 90% of the data are captured 
directly from the electronic medical record systems, which minimizes the risk of data 
entry errors. The registry was used in study II and III to assess the patients’ different 
levels of the exposures HbA1c and albuminuria. Furthermore, the registry was used 
to assess patient characteristics such as body mass index, blood pressure, and lipid 
status.  The outpatient clinics have had an obligation to report to the registry since 
2004. General practitioners have reported to the registry since 2006, however, it did 
not become mandatory before 2014. Therefore, the data coverage from outpatient 
clinics is generally high, whereas the data coverage from general practice is still 
limited.65 
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The study populations of study I-III comprised Danish patients with diabetes. In study 
I, the source population was patients with diabetes identified based a combination of 
ICD-10 diagnostic codes for diabetes in the Danish National Patient Registry and 
ATC-codes for claimed prescriptions of glucose-lowering drugs from the Danish 
National prescription registry. From the source population of diabetes patients, we 
included all inpatients and outpatients registered in the Danish National Patient 
Registry who were discharged with a hospital diagnosis of non-valvular atrial 
fibrillation from January 1, 2005 to December 31, 2015. The index date (baseline) 
was defined as the date of the incident atrial fibrillation diagnosis. The specific 
exclusion criteria are described in Table 1.  
In study II, the source population comprised patients with type 2 diabetes identified 
through the Danish Adult Diabetes Registry. From the source population of type 2 
diabetes patients, we included all inpatients and outpatients registered in the Danish 
National Patient Registry who were discharged with a hospital diagnosis of non-
valvular atrial fibrillation from May 1, 2005 to December 31, 2015. The index date 
was defined as the date of the incident atrial fibrillation diagnosis. The specific 
exclusion criteria are described in Table 1. 
In study III, the source population comprised patients with type 2 diabetes identified 
through the Danish Adult Diabetes Registry. From the source population of type 2 
diabetes patients, we included all patients that were registered with two consecutive 
measurements of the UACR or UAE within 15 months during the inclusion period of 
May 1, 2005 to June 30, 2015. The index date was defined as the date of the latter 
albuminuria measurement. The specific exclusion criteria are described in Table 1. 
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Table 1. Overview of study populations for study I-III  
* Immigration within one year before entrance in the study. †patients who were baseline users of 
anticoagulation treatment were excluded to assess ischaemic stroke risk in atrial fibrillation free from stroke 
prevention treatment. ‡Patients with anaemia or end stage kidney disease were excluded because HbA1c 
values can be misleadingly low in this patient group. CRS: The Danish Civil Registration System. 
 
Type of diabetes  
In study I, patients were identified as patients with type 1 diabetes or type 2 diabetes 
by using an algorithm developed by the Danish Health Data Authority (see Appendix 
A).68 The algorithm is based on a combination ICD-10 diagnostic codes for diabetes 
and ATC codes for claimed prescriptions of glucose-lowering drugs.  
Glycaemic status 
In study II, glycaemic status was determined with HbA1c measurements from the 
Danish Adult Diabetes Registry. A patient’s baseline HbA1c value was determined as 
the most recent HbA1c measurement within two years before inclusion or the first 
HbA1c measurement within four weeks after inclusion. HbA1c values were 
categorized according to the clinical cut points suggested by the National Institute for 
Health and Care Excellence guidelines (HbA1c ≤48 mmol/mol, HbA1c = 49-58 
mmol/mol, and HbA1c >58 mmol/mol) and also investigated as a continuous 
variable.69 
Study Period  Population  Exclusion Criteria 
I January 1, 2005 to 
December 31, 2015 
Diabetes and 
incident non-
valvular atrial 
fibrillation  
• Valvular atrial fibrillation 
• Inconsistent information from CRS 
• Patients not habitually residing in 
Denmark* 
• Ischaemic stroke/systemic embolism 
on index date 
• Prior anticoagulation treatment†  
 
II May 1, 2005 to 
December 31, 2015 
Type 2 diabetes and 
incident non-
valvular atrial 
fibrillation  
• Valvular atrial fibrillation 
• Inconsistent information from CRS 
• Patients not habitually residing in 
Denmark* 
• Ischaemic stroke/systemic embolism 
on index date 
• Anaemia or end stage kidney 
disease‡ 
• No available HbA1c measurements 
within the past two years before or 
four weeks after inclusion. 
 
III May 1, 2005 to 
June 30, 2015 
Type 2 diabetes 
patients with two 
consecutive 
measurements of the 
UACR or the UAE 
within 15 months  
• Prior diagnosis of ischaemic stroke, 
ischaemic heart disease, or 
peripheral arterial disease 
• Inconsistent information from CRS 
• Patients not habitually residing in 
Denmark*   
CHAPTER 3. METHODS 
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Albuminuria status  
In study III, patients were categorised in the following categories: Normoalbuminuria 
(UAE <30 mg/day or UACR <30 mg/g), microalbuminuria (UAE = 30-299 mg/day 
or UACR of 30-299 mg/g), and macroalbuminuria (UAE ≥300 mg/day or UACR 
≥300 mg/g).  
 
In all three studies, patients were followed in the Danish National Patient Registry for 
the occurrence of ischaemic stroke. Furthermore, systemic embolism was an outcome 
in study I and II and myocardial infarction and death was an outcome in study III. We 
only used primary diagnoses of the outcomes as the primary diagnosis is the main 
reason for the hospital contact. We did not use secondary diagnoses as they are a 
supplement to the primary diagnosis and therefore meant to express diseases related 
to the current hospital contact.62 Therefore, secondary diagnoses are more likely to be 
an expression of a prior event of the outcome under study. Patients were followed 
from their individual index date to the occurrence of an outcome event, emigration, 
death, or end of follow-up (31th of December 2015), which ever came first. 
Furthermore, initiation of anticoagulation treatment was considered as a censoring 
event in study I, to focus on non-anticoagulated patients.    
 
In all studies, we assessed the incidence rates of the outcomes under study. The 
incidence rate of the outcome under study during a specific time interval was 
calculated as the number of events occurring during that time interval divided by the 
total observation time in that same interval.  
For the purpose of assessing the association between the different exposures and 
outcomes of interest we used time-to-event analysis. Specifically, we used the Cox 
regression model. In Cox regression the hazard rate among exposed is compared with 
the hazard rate among non-exposed. The hazard rate it determined as the rate 
(probability per unit time) of experiencing a specific event at time t among all subjects 
who have not experienced any prior event up to time t. Hazard rates are calculated in 
a dynamic population, the ‘at risk’ population, as opposed to cumulative risk which is 
derived from fixed cohorts and relative to the baseline population. The hazard rate can 
be viewed as the average frequency or “speed” with which an event occurs and it is 
often referred to as the instantaneous risk of a given outcome.70 In a Cox regression 
model no assumption is made about the underlying hazard function. This particular 
property results in the underlying assumption that the hazards in different exposure 
groups must be proportional throughout the study. We checked the proportional 
hazard assumption for all covariates in all studies with visual inspection of log-log 
plots. The underlying time axis in the Cox proportional hazard models was time since 
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inclusion into the study, and, as such, either time since incident atrial fibrillation 
(study I and II) or time since the latter albuminuria measurements (study III).  
In study II and III, extreme outliers of body mass index and systolic blood pressure 
(susceptible to erroneous registration) were categorized as missing variables. Missing 
variables of body mass index, smoking status, systolic blood pressure, and HbA1c 
were handled with the ‘missing indicator’ method. When using the ‘missing indicator’ 
method to handle missing covariate data, missing observations are set to a fixed value, 
and an extra dummy variable is added to the multivariable model to indicate whether 
the value for that variable is missing. 
In all analyses, we adjusted for selected risk factors or available confounders as 
appropriate. In study I, we sought to establish whether type of diabetes was associated 
with ischaemic stroke independently of the factors in the current European stroke risk 
stratification tool (the CHA2DS2-VASc score) in atrial fibrillation. Therefore, we 
included the CHA2DS2-VASc score components (congestive heart disease, 
hypertension, age, ischaemic stroke, vascular disease, and sex) and antiplatelet 
treatment in the Cox regression analysis. As we did not seek to investigate an 
aetiological relationship between type of diabetes and the risk of ischaemic stroke, we 
did not adjust for all factors that may confound the association between type of 
diabetes and the risk of thromboembolism.    
In study II, we aimed to elucidate the aetiological relationship between glycaemic 
status and the risk of thromboembolism. Therefore, we adjusted for all available 
confounders that were selected a priori based on current literature, including 
congestive heart failure, hypertension, prior ischaemic stroke/transient ischaemic 
attack, vascular disease, sex, chronic kidney disease, smoking status, body mass 
index, age, diabetes  duration, statin treatment, antiplatelet treatment, metformin 
treatment, and anticoagulation treatment. 
In study III, we sought to examine the association between albuminuria and 
cardiovascular events/all-cause mortality, independent of other known risk factors for 
these outcomes. Therefore, we adjusted for other known cardiovascular risk factors. 
Adjustment was applied in different steps: model 1 included: Age and sex; model 2 
included: Cardiovascular risk profile (in addition to the variables included in model 1 
we adjusted for atrial fibrillation, congestive heart failure, diabetes duration, HbA1c, 
body mass index, smoking status, low-density lipoprotein cholesterol, systolic blood 
pressure); model 3 included: Cardiovascular risk profile and cardiovascular 
preventive treatment (in addition to the variables included in model 2 we adjusted for 
anticoagulation treatment, antiplatelet treatment, angiotensin-converting enzyme 
inhibitors/ angiotensin-receptor blockers). 
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Data were analysed with Stata Statistical Software: Release 14 (College Station, TX: 
StataCorp LP) and R version 3.3.3 (R Foundation for statistical Computing, Vienna, 
Austria). Results are reported with 95% confidence intervals (CIs). 
Secondary analyses 
In study I, we performed a secondary analysis where patients were stratified by 
baseline age into categories of:  age <65 years, 65-74 years, and ≥75 years. The 
purpose of this analysis was to elucidate whether the association between type of 
diabetes and thromboembolism differed among different age groups.    
In study II, we performed a secondary analysis where patients were stratified by 
baseline duration of diabetes into categories of:  diabetes duration <10 years and ≥10 
years. The purpose of this analysis was to examine whether the association between 
glycaemic status and thromboembolism differed among patients with different 
duration of diabetes. We chose the arbitrary cut point of <10 years and ≥10 years of 
diabetes duration based on evaluations of the clinical trials investigating the effect of 
intensive glycaemic control on the risk of cardiovascular disease in patients with 
diabetes. The evaluation of these trials have suggested that the primary effect of 
intensive treatment was within patients with a shorter duration of diabetes, which was 
also estimated to be a cut point of approximately 10 years.71  
Sensitivity analyses 
In study I, we classified patients as either type 1 or type 2 diabetes with the use of an 
algorithm developed by the Danish Health Data Authority,68 however, after the initial 
classification around 24% of the patients with type 1 diabetes were baseline users of 
an oral glucose-lowering drug. Patients using oral glucose lowering drugs are most 
likely to be patients with type 2 diabetes, which may indicate that we misclassified 
some patients. To assess whether our analysis was affected by misclassification of the 
exposure groups, we relocated all baseline users of oral blood glucose-lowering drugs 
in the ‘type 1 diabetes’ group to the ‘type 2 diabetes’ group.  
In study II, we restricted the study population to patients who had an HbA1c 
measurement within the past year before or 4 weeks after a first-time atrial fibrillation 
diagnosis. The analysis was intended to assess whether the use of up to two years old 
HbA1c measurements induced misclassification of the exposure. Furthermore, the  
baseline characteristics of patients who were excluded due to not having a HbA1c 
measurement within the past two years before or 4 weeks after index date was 
compared to the baseline characteristics of the included patients. We performed this 
analysis to assess whether our results could be generalized to a broad population of 
patients with type 2 diabetes and incident atrial fibrillation.  
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In study III, we repeated the approach in the main analysis for patients with a 
consistent albuminuria category in both albuminuria measurements. This analysis was 
intended to assess whether the uncertain exposure categorization induced 
misclassification bias in the main analysis.  
 
The studies were approved by the Danish Data Protection Agency, file No. 2008-58-
0028. In Denmark, no ethical approval is required for anonymous registry studies.   
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CHAPTER 4. TYPE OF DIABETES AND 
RISK OF ISCHAEMIC STROKE IN 
ATRIAL FIBRILLATION  
As outlined in Chapter 1, patients with atrial fibrillation and comorbid diabetes have 
a higher risk of ischaemic stroke compared to those without diabetes. However, 
estimated incidence rates have varied considerably ranging between 3.6 and 8.6 per 
100 person-years in different studies.72 The observed risk difference might be related 
to the diversity of the diabetes population, underlining the need to improve stroke risk 
stratification in patients with diabetes and atrial fibrillation.  
In study I, we aimed to examine whether type 1 and type 2 diabetes were associated 
with different risks of thromboembolism among patients with incident nonvalvular 
atrial fibrillation. In the following section, the results of study I will be presented and 
discussed in relation to other studies that have aimed to identify prognostic factors for 
ischaemic stroke in patients with atrial fibrillation and diabetes.   
 
In patients with atrial fibrillation, the European Society of Cardiology guidelines 
currently recommend to assess the risk of ischaemic stroke with the CHA2DS2-VASc 
score.59 The CHA2DS2-VASc score is a point based prediction model that allocates 
one point for each of the risk factors; congestive heart failure, hypertension, diabetes, 
vascular disease, age 65 to 74 years, and female sex, and two points for age ≥75 years 
and previous ischaemic stroke, systemic embolism, and/or transient ischaemic attack. 
The guideline-recommended function of the prediction model is to assist the clinician 
in deciding whether or not to initiate oral anticoagulation treatment in patients with 
atrial fibrillation. The underlying principle is that the benefit from the expected 
absolute reduction in ischaemic stroke risk from oral anticoagulation treatment must 
exceed the expected harm from the increased risk of bleeding associated with the 
treatment itself. Currently, there is strong evidence to support that the high-risk group 
of patients with a CHA2DS2-VASc score of 2 or more in men, and 3 or more in women 
will benefit from treatment with oral anticoagulants.73–76 Benefits are less clear in 
patients with a CHA2DS2-VASc score of 1 for men, and 2 for women.77 Currently, the 
European guidelines recommend that oral anticoagulation treatment should be 
considered for this group, weighing the expected stroke risk reduction, bleeding risk, 
and patient preference.59 The lack of clear-cut recommendations for this group of 
patients arise from the substantial variation of observed ischaemic stroke risk in 
various studies of patients with atrial fibrillation and a CHA2DS2-VASc score of 1. 
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Observed rates per 100 person-years from currently available studies in patients with 
a CHA2DS2-VASc score of 1 have ranged from 0.1 to 6.6.78 Similarly, rates per 100 
person-years for patients with a CHA2DS2-VASc score of 0 have ranged from 0.04 to 
2.4.79 As these event rates emerge from various data sources, the large variation in 
events rates may in part be due the variations in the validity of the stroke diagnosis in 
administrative databases and in particular methodological differences in study 
design.80,81 However, it is also conceivable that the score is poorly calibrated across 
different cohorts. Calibration is the degree to which the predicted risk of the score 
matches the observed risks across the range of risk scores. In that regard, overall 
calibration of the CHA2DS2-VASc score is of less clinical importance as the primary 
function of the CHA2DS2-VASc score is identify patients who are at a ‘truly low risk’ 
and will not have a net clinical benefit from anticoagulation treatment. However, as 
observed rates per 100 person years in patients with a CHA2DS2-VASc score of 0 or 
1 have ranged both above and below the suggested ‘tipping point’ for anticoagulation 
treatment (0.9 for dabigatran and 1.7 for warfarin)82 there seems to be room for 
improvement. 
A potential source of the mediocre performance of the CHA2DS2-VASc score may be 
the simple dichotomising of the risk factors incorporated in the score. This is the case 
for patients with diabetes. Diabetes is simply dichotomized into presence or absence 
of diabetes. Nonetheless, the diabetes population is diverse as it includes patients with 
different types of diabetes, varying duration of disease, and varying levels of 
glycaemic control. Assuming that all patients with diabetes and atrial fibrillation have 
the same risk of ischaemic stroke is a simplistic approach. Thus, for the purpose of 
risk stratification for ischaemic stroke prevention among patients with diabetes, the 
CHA2DS2-VASc score may be viewed as a too simple tool. The simplicity may allow 
for ease of use, which has been proposed to improve adherence to guideline 
recommendations.83 However, the lack of granularity of the CHA2DS2-VASc score 
may give rise to treatment decisions that are suboptimal for the individual patient. As 
anticoagulation treatment is potentially a life-long treatment with a consequential 
increased bleeding risk, precision in risk stratification trumps ease of use. Thus, 
further development of the tool to improve the predictive performance may facilitate 
better risk stratification in the specific subgroup of patients with both atrial fibrillation 
and diabetes and thereby optimize clinical decisions about antithrombotic treatment 
in every day clinical practice. 
 
Depending on the population studied the risk of ischaemic stroke in patients with 
diabetes and atrial fibrillation has varied considerably.72,84–89 This is, however, not 
surprising as the diabetes population includes patients with different metabolic 
disorders. The majority of diabetes patients can be divided into type 1 and type 2 
diabetes, diseases with different distribution of cardiovascular risk factors that are not 
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included in the current risk stratification tool. Patients with type 1 and type 2 diabetes 
may differ with regard to their duration of disease, physical activity level, body mass 
index, and presence of dyslipidaemia. These factors have been associated with a 
higher ischaemic stroke risk in atrial fibrillation,90–93 but whether that translates into 
differences in the ischaemic stroke risk among patients with atrial fibrillation and type 
1 or type 2 diabetes is unknown. To explore whether the type of diabetes could serve 
as an easily available clinical risk prediction marker, we aimed to investigate whether 
subdividing patients into categories of type 1 and type 2 diabetes would provide 
additional prognostic information beyond the CHA2DS2-VASc score.  
Results of study I 
In study I, we identified 10,058 non-anticoagulated patients with a prior diagnosis of 
diabetes and an incident nonvalvular atrial fibrillation diagnosis. A total of 762 (7.6%) 
patients had a thromboembolic event during the three years of follow-up. Incidence 
rates of thromboembolism at one and three-year follow-up, both overall and stratified 
by age, are listed in Table 2. Incidence rates generally attenuated at three-years of 
follow-up, indicating that most events occurred early in the follow-up period after the 
atrial fibrillation diagnosis. Overall, we did not find a difference in the risk of 
thromboembolism when comparing patients with type 2 diabetes to patients with type 
1 diabetes (Table 3). However, in an additional age stratified analysis we found that 
in patients aged <65 years, type 2 diabetes was associated with a higher risk of 
thromboembolism as compared with type 1 diabetes.   
 
 
 1 year follow-up 3 year follow-up 
 Type 1  
diabetes  
Type 2  
diabetes  
Type 1  
diabetes  
Type 2  
diabetes  
Total population      
  Number of patients 1,277 8,781 1,277 8,781 
  Events no.  73 543 86 676 
  Incidence rate 12.49 14.32 7.15 8.62 
Age <65 years     
  Number of patients 342 1,403 342 1,403 
  Events no.  12 54 13 74 
  Incidence rate 6.20 8.26 2.91 5.01 
Age 65-74 years     
  Number of patients 393 2,487 393 2,487 
  Events no.  24 157 31 186 
  Incidence rate 15.26 15.36 9.90 8.69 
Age ≥75 years     
  Number of patients 542 4,891 542 4,891 
  Events no.  37 332 42 416 
  Incidence rate 15.83  15.70 9.45 9.85 
Table 2. Crude incidence rates per 100 person-years of thromboembolism at one- and 
three-year follow-up, overall and stratified by age 
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Table 3. Hazard ratios (95% CI) of thromboembolism at one- and three-year follow-
up, overall, and stratified by age (reference: type 1 diabetes)  
The analyses were adjusted for the components of the CHA2DS2-VASc score (congestive heart failure, 
hypertension, age [continuous covariate], prior ischaemic stroke/transient ischaemic attack, myocardial 
infarction/peripheral artery disease, and female sex) and baseline use of antiplatelet treatment.  
In a sensitivity analysis, we reassigned around 24% of the patients with type 1 diabetes 
to the group with type 2 diabetes because they had a prescription of an oral glucose-
lowering drug. The results were similar to those of the main analysis, with an adjusted 
HR of thromboembolism of 1.09 (95% CI: 0.85-1.40) when comparing type 2 diabetes 
with type 1 diabetes. 
Discussion  
Overall, our results do not suggest that the type of diabetes was associated with 
different risks of ischaemic stroke when adjusting for the individual risk factors in the 
CHA2DS2-VASc score. However, we did find a higher risk of ischaemic stroke in 
patients with type 2 diabetes in the subset of patients aged less than 65 years. This is 
the subset of patients for whom the observed thromboembolism risk is usually the 
lowest and therefore most uncertainty about initiation of anticoagulation treatment 
exist in this particular group. In that respect, replication of our study findings is of 
interest to extend the clinical evidence specifically in this subgroup.   
Although, no other studies have specifically focused on type of diabetes as a predictor 
of ischaemic stroke in atrial fibrillation, several studies have focused on identifying 
stroke risk predictors among patients with diabetes and atrial fibrillation. Some studies 
have specifically aimed for refining the CHA2DS2-VASc score, whereas other studies 
have focused on identifying diabetes-related risk factors that may be associated with 
a higher ischaemic stroke risk, independently of other known stroke risk factors. 
Currently, factors such as duration of diabetes, glycaemic status, and microvascular 
complications have been investigated (see Table 4 for an overview of the results of 
other studies).94–98 For instance, Overvad et al. investigated whether duration of 
diabetes could refine the CHA2DS2-VASc score in a large Danish register based 
study.94 They found a clear dose-response relationship between duration of diabetes 
and the risk of ischaemic stroke after adjusting for the individual factors in the 
CHA2DS2-VASc score. Similarly, Ashburner et al. found that a duration of diabetes 
over three years was associated with a higher rate of ischaemic stroke when adjusting 
for several risk factors for ischaemic stroke including the individual elements of the 
CHA2DS2-VASc score.95 Ashburner et al. also investigated the association between 
 
 1 year follow-up 3 year follow-up  
Overall  1.10 (0.85-1.40) 1.15 (0.91-1.44) 
Age <65 years 1.47 (0.77-2.79) 2.01(1.09-3.68) 
Age 65-74 years 1.07 (0.69-1.65) 1.00 (0.68-1.47) 
Age ≥75 years 1.02 (0.73-1.44) 1.09 (0.79-1.50) 
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glycaemic status as reflected by HbA1c, but did not find a difference in the risk of 
ischaemic stroke in different categories of HbA1c after adjustment for several known 
risk factors for ischaemic stroke. This finding is in contrast to the findings of Saliba 
et al. who performed a large register based study in Israel where HbA1c in quartiles 
exhibited a dose-response relationship with the risk of ischaemic stroke and when 
added to CHA2DS2-VASc score helped to improve the predictive accuracy.96 Their 
finding is supported by our results in study II, where we observed a dose-response 
relationship between HbA1c levels and the risk of ischaemic stroke. However, only 
among patients with shorter duration diabetes. This result may suggest that HbA1c 
would only be a meaningful stroke risk marker in the subgroup of patients with 
diabetes duration under 10 years.  
Not only diabetes duration and glycaemic status display a potential for refining stroke 
risk prediction in atrial fibrillation and diabetes. Subdivision of patients into groups 
of insulin-treated and noninsulin-treated diabetes may also be a potential approach for 
breaking down the diabetes category in the CHA2DS2-VASc score.  This approach 
was examined by Patti et al. and Mentias et al. who both found that insulin-treated 
diabetes was associated with a higher risk of ischaemic stroke compared with 
noninsulin-treated diabetes.99 It serves mentioning that insulin treatment itself may 
not be causally associated with an increased risk of ischaemic stroke, but is more 
likely to be a proxy measure for severity of type 2 diabetes and the degree of insulin 
resistance. Another marker of severity of disease is the presence of retinopathy, 
nephropathy, and neuropathy in patients with atrial fibrillation and diabetes. Two 
studies have examined the association between the presence of these microvascular 
complications and the risk of ischaemic stroke.97,98 After adjusting for several risk 
factors also beyond those embedded in the CHA2DS2-VASc score, the risk of 
ischaemic stroke was similar between patients with and without microvascular 
complications. Thus, the presence or absence of retinopathy, nephropathy, and 
neuropathy may be less suitable for refining stroke risk stratification in diabetes and 
atrial fibrillation. 
The current literature clearly indicate that the risk of ischaemic stroke is not uniform 
in patients with diabetes and atrial fibrillation. It also illustrates the potential for 
including other factors in risk stratification of patients with diabetes and atrial 
fibrillation. Potential risk factors may include diabetes duration, glycaemic status, 
type of diabetes, and insulin versus non-insulin treated diabetes. These factors have 
the advantage of being readily available in everyday clinical practice. Moreover, these 
potential risk markers are reasonably evenly distributed in a diabetes population 
making them suitable for risk prediction. Identifying risk prediction markers that are 
only prevalent in a minority of the population would provide little clinical value. 
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Table 4. Overview of studies investigating prognostic factors for ischaemic stroke or 
systemic embolism in patients with diabetes and atrial fibrillation  
* Incidence Rates are per 100 person-years. †HbA1c units are converted from DCCT (Diabetes Control 
and Complication) units to IFFC (International Federation of Clinical Chemistry) units.102 CI: Confidence 
interval.   
  
 Definition of subdivision Incidence 
rate* 
Hazard Ratio 
(95% CI) 
Saliba et al.96  Glycated haemoglobin†    
 No diabetes  2.59 1 (reference) 
 Quartile 1 (<46 mmol/mol) 3.22 1.04 (0.83-1.30) 
 Quartile 2 (46-52 mmol/mol) 3.51 1.14 (0.92-1.42) 
 Quartile 3 (52-61 mmol/mol) 4.50 1.46 (1.19-1.79) 
 Quartile 4 (>61 mmol/mol) 4.56 1.63 (1.33-2.00) 
Fangel et al.100 Glycated haemoglobin & 
diabetes duration<10 years 
  
 HbA1c <48 mmol/mol  1.44 1 (reference) 
 HbA1c = 49-58 mmol/mol  2.88 2.38 (1.54-3.70) 
 HbA1c >58 mmol/mol  2.73 2.58 (1.55-4.28) 
 Glycated haemoglobin & diabetes duration 
≥10 years 
  
 HbA1c ≤48 mmol/mol  3.07 1 (reference) 
 HbA1c = 49-58 mmol/mol  2.47 0.86 (0.55-1.35) 
 HbA1c >58 mmol/mol  2.75 0.96 (0.62-1.48) 
Ashburner et 
al.95 
Glycated haemoglobin*    
HbA1c <53.0 mmol/mol 2.6 1 (reference) 
HbA1c = 53.0-74.9 mmol/mol 2.9 1.21 (0.77-1.91) 
HbA1c ≥75.0 mmol/mol 2.9 1.04 (0.57-1.92) 
Diabetes duration    
No diabetes  1.8 1 (reference) 
Diabetes duration <3 years 1.9 1.15 (0.84-1.58) 
Diabetes duration ≥3 years 3.2 1.63 (1.29-2.05) 
Overvad et al.94  Diabetes duration   
 No diabetes mellitus  2.4 1 (reference) 
 Diabetes duration 0-4 years 2.8 1.11 (1.03-1.20) 
 Diabetes duration 5-9 years 3.7 1.32 (1.20-1.44) 
 Diabetes duration 10-14 years 4.0 1.28 (1.13-1.45) 
 Diabetes duration ≥15 years 4.5 1.48 (1.29-1.70) 
Lip et al.98  Retinopathy    
 No retinopathy 4.16 1 (reference) 
 Retinopathy 4.86 1.21 (0.80-1.84) 
Chou et al.97 Microvascular complications    
 None  4.65 1 (reference) 
 Retinopathy 5.07 1.11 (0.95-1.30) 
 Nephropathy 4.77 1.03 (0.93-1.14) 
 Neuropathy 5.20 1.15 (1.07-1.24) 
Patti et al.99 Insulin- vs. noninsulin-requiring diabetes    
 Noninsulin-requiring diabetes  1.8 1 (reference) 
 Insulin-requiring diabetes  5.2 2.96 (1.49-5.87) 
Mentias et al.101 Insulin- vs. noninsulin-requiring diabetes    
Noninsulin-requiring diabetes  2.3 1 (reference) 
Insulin-requiring diabetes  2.6 1.15 (1.09-1.20) 
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However, several limitations concerning the available evidence serves mentioning. 
Firstly, the potential prediction markers have only been investigated in a few 
population-based studies. Several of these studies did not include incident atrial 
fibrillation,95,96,99 which may underestimate true stroke risk as several studies have 
shown that the risk of ischaemic stroke is higher in the first year after initial onset of 
atrial fibrillation.103–105  
Secondly, a critical limitation in current evidence is the handling of patients on 
anticoagulation treatment in the available studies. As it is universally accepted that 
anticoagulation treatment is beneficial for high-risk atrial fibrillation patients, 
completely non-anticoagulated cohorts of patients do not exist. Therefore, studies may 
either choose to focus on mixed cohorts of both anticoagulated and non-
anticoagulated patients or strictly evaluate ischaemic stroke risk in non-anticoagulated 
cohorts.81 In study I and some of the other studies, non-anticoagulated cohorts were 
used to asses ischaemic stroke risk,95–97 whereas others looked at mixed cohort of both 
anticoagulated and non-anticoagulated patients.94,98,99 On one hand, studies including 
only patients who are not using anticoagulants, may result in a selected subtype of 
atrial fibrillation patients including low-risk patients and patients in whom the 
clinician is reluctant to initiate oral anticoagulant treatment. On the other hand, in 
studies of mixed cohorts where a large proportion or the majority of the patients were 
receiving anticoagulation, the results may not be applicable to patients with diabetes 
and atrial fibrillation who are not anticoagulated. This is a particularly important 
concern, since anticoagulant treatment decision rely on observed risks of ischaemic 
stroke in untreated populations. In study I, we chose not to include patients already 
receiving anticoagulants and furthermore, we censored patients when they initiated 
anticoagulation treatment. This approach was chosen because the CHA2DS2-VASc 
score is recommended by the guidelines for stroke risk assessment prior to 
anticoagulant treatment decisions in patients with atrial fibrillation. However, this 
choice limits the external validity of the study results.  
Thirdly, an inherent problem in current literature is the lack of focus on ischaemic 
stroke subtype.106 Although the majority of ischaemic strokes (up to 80%) in atrial 
fibrillation are presumed to be of cardioembolic origin,  ischaemic strokes of other 
origins also occur.107,108 Neither clinical trials nor the cohort studies seeking to identify 
‘truly low risk’ patients have accounted for potential differences in observed results 
based on stroke subtypes. As diabetes is a strong risk factor for developing 
atherosclerotic cardiovascular disease and several studies have shown that in non-
atrial fibrillation populations diabetes is associated with non-cardioembolic 
strokes,50,109,110 but not cardioembolic strokes,49,50 it raises the question whether the 
observed increased risk of stroke in prior cohort studies including diabetes patients 
and in study I and II are in fact cardioembolic. As oral anticoagulants primarily 
prevent ischaemic strokes of cardioembolic origin, ignoring stroke subtype could 
theoretically lead to suboptimal treatment decision for patients with atrial fibrillation 
and a concomitant strong atherosclerotic risk profile.  
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Finally, several studies did not aim to specifically refine the CHA2DS2-VASc score, 
but merely to clarify whether an association between the risk factor under study and 
ischaemic stroke was present, independent of other known risk factors. Thus, whether 
these risk factors would refine stroke risk stratification with the CHA2DS2-VASc 
score is unknown. Moreover, the accuracy of a model is often only modestly improved 
when the added novel risk factor is positively correlated with the existing predictor 
variables.111 Thus, it is unclear whether the above-mentioned risk factors would 
provide additional information when added simultaneously to the same risk score. In 
that regard, testing all factors together in a single study to elucidate which factors 
improve risk prediction the most is warranted.106 Evaluation of the performance of an 
extended prognostic model by testing the calibration of an extended model is also 
necessary. In terms of evaluating the predictive ability of the CHA2DS2-VASc score, 
focus has primarily been on determining the discriminative performance of the 
CHA2DS2-VASc score that is, the ability to rank people correctly in order of their risk 
and separate those who will develop an event from those who will not.79 The 
discriminative performance of the CHA2DS2-VASc score has been estimated to be 
modest with a pooled C-statistics of 0.64 in general populations and 0.71 in a hospital 
setting.112 However, from a clinical point of view the discriminative performance is 
of less interest as it does not directly influence treatment decisions. We did not 
evaluate the discriminative ability of a refined model in study I. As no prior studies 
have explored whether an association between the type of diabetes and risk of 
thromboembolism exist, we chose to start out by elucidating whether there was an 
association and whether that association was of a clinically meaningful magnitude.113 
Moreover, even though a novel risk factor only provides little or no improvement in 
the discriminative performance of the model, it does not exclude that novel risk factor 
from improving the usefulness of the model.114  
Another concern may be the application of an extended model. Adding factors to the 
CHA2DS2-VASc score would add complexity and thereby make everyday use in the 
clinical practice more complicated. This may raise the concern that the application of 
the score would decrease. However, digital tools derived from e.g. machine learning 
and implemented through digital administrative registries may accommodate even 
more advanced risk prediction models in the future without compromising their use 
in everyday clinical practice.115  
As previously stated, it is currently recommended that patients with atrial fibrillation 
and a CHA2DS2-VASc score of 1 should be considered for anticoagulation treatment, 
balancing stroke risk, bleeding risk, and patient preference. This makes all patients 
with diabetes potential candidates for life long anticoagulation treatment. The  
observed incidence rates of ischaemic stroke associated with diabetes in the studies of 
patients with diabetes and atrial fibrillation with a CHA2DS2-VASc score of 1 have 
ranged well above the current recommendation of 1 to 2 per 100 person years.84,116 In 
study I, we also observed incidence rates for all subgroups that ranged well above the 
treatment recommendations. Based on these observations, having 1 point due to 
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diabetes may in itself carry a magnitude of risk that indicates a net clinical benefit 
from oral anticoagulation treatment. Nonetheless, the presence of type 2 diabetes 
should perhaps favour initiation of anticoagulation compared with type 1 diabetes, 
specifically in cases of doubt regarding initiation of oral anticoagulation.  
In conclusion, study I showed no overall association between the type of diabetes and 
the risk of thromboembolism among patients with atrial fibrillation. However, among 
the subgroup of patients aged below 65 years, type 2 diabetes was associated with a 
higher risk of thromboembolism when compared with type 1 diabetes. Patients aged 
below 65 years are usually patients with the lowest risk of thromboembolism. Hence, 
most uncertainty about the benefit of anticoagulation treatment is related to this group 
of patients and our findings indicate that type 2 diabetes is associated with a higher 
risk of thromboembolism than type 1 diabetes in this particular group. The combined 
results of study I and the other above-mentioned studies provides a perspective on 
how risk prediction might be improved regarding the subpopulation of diabetes 
patients with atrial fibrillation. The observed associations suggest that adding factors 
like insulin-treated diabetes, diabetes duration, and HbA1c level may provide better 
prediction of ischaemic stroke in patients with atrial fibrillation than the simple 
presence or absence of diabetes. However, there is a need for further validation of 
current findings, specifically whether adding these factors to the CHA2DS2-VASc 
score may facilitate identification of ‘truly low-risk’ patients in the diabetes subgroup, 
who may be better off without anticoagulation, as opposed to the current approach 
where all diabetes patients are potential candidates for life long oral anticoagulation. 
At present, there is not enough evidence to support a subdivision of diabetes patients 
according to diabetes related factors and diabetes should continue to be incorporated 
into CHA2DS2-VASc score as an entity.
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CHAPTER 5. GLYCAEMIA AND RISK 
OF THROMBOEMBOLISM IN ATRIAL 
FIBRILLATION 
As outlined in Chapter 4, diabetes has been associated with a higher risk of ischaemic 
stroke in patients with atrial fibrillation.72,84–89 However, the underlying biological 
aspects that explain the link between diabetes and thromboembolic events are unclear. 
Chronic exposure to raised concentrations of glucose has been suggested to contribute 
to the development of ischaemic stroke and the association between elevated HbA1c 
and ischaemic stroke in patients with diabetes has been studied extensively showing 
a clear dose-response relationship.117–120 Moreover, it has been suggested that the risk 
of ischaemic stroke is increased in patients with diabetes and hyperglycaemia, but not 
in those without hyperglycemia.121 Hence, the presence of hyperglycaemia in diabetes 
may in part explain the increased risk of ischaemic stroke in patients with diabetes.     
Whether hyperglycaemia contributes to the development of ischaemic stroke in 
patients with atrial fibrillation, where the origin of ischaemic strokes are 
predominantly cardioembolic, is unclear.107,108 A few studies have examined the 
relationship between glycaemic status and the risk of ischaemic stroke with 
conflicting findings.95,96 In study II, we addressed this discrepancy, by exploring the 
effect of glycaemic status on the risk of thromboembolism in patients with atrial 
fibrillation and type 2 diabetes. In the following section, the results of study II will be 
presented and discussed in perspective to other studies that have aimed to examine the 
association between HbA1c and the risk of ischaemic stroke in patients with atrial 
fibrillation and diabetes.   
Results of study II 
The study population included 5,386 patients with incident nonvalvular atrial 
fibrillation and type 2 diabetes. The incidence rates per 100 person-years increased in 
a dose-response manner across increasing levels of HbA1c (Table 5). Compared with 
patients with HbA1c <48 mmol/mol, we observed a higher risk of thromboembolism 
among patients with HbA1c = 49-58 mmol/mol and HbA1c >58 mmol/mol in the 
adjusted Cox regression analysis (Table 6). In analyses stratified by diabetes duration, 
a strong association between elevated levels of HbA1c and thromboembolism was 
found in patients with diabetes duration of <10 years. In contrast, we observed no 
difference in thromboembolic risk across different levels of HbA1c among patients 
with a diabetes duration of ≥10 years.  
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Table 5. Crude incidence rates per 100 person-years of thromboembolism at five-year 
follow-up, overall and stratified by diabetes duration    
 
Table 6. Hazard ratios (95% CI) of thromboembolism at five-year follow-up, overall 
and according to diabetes duration (reference: HbA1c ≤48)  
The analysis was adjusted for congestive heart failure, hypertension, prior stroke/transient ischaemic attack, 
vascular disease, sex, chronic kidney disease, smoking status, body mass index, age, diabetes duration, 
statin treatment, antiplatelet treatment, metformin treatment, and anticoagulation treatment. 
 
Sensitivity analysis 
In a sensitivity analysis, we repeated the approach in the main analysis for the 3,857 
patients who had an HbA1c measurement within the year before or four weeks after 
a first-time atrial fibrillation diagnosis. The results were similar to the main analysis 
with HR of 1.42 (95% CI: 0.98-2.06) and HR of 1.50 (95% CI: 1.02-2.22) for patients 
with HbA1c = 49-58 mmol/mol and HbA1c >58 mmol/mol, respectively. In addition, 
the baseline characteristics of patients excluded due to missing HbA1c values were 
assessed. On average this population was younger, had a shorter duration of diabetes, 
had a lower prevalence of comorbidity, and received less medication than the patients 
who were included in the study (data not shown).   
 
 
 
 
 
HbA1c ≤48 
mmol/mol 
HbA1c 49-58 
mmol/mol 
HbA1c >58 
mmol/mol 
Total population     
  Number of patients  2,120 1,657 1,609 
  Events no.  74 91 98 
  Incidence rate 1.92  2.66  2.74  
Diabetes duration <10 years     
  Number of patients  1,428 782 465 
  Events no. 39 47 29 
  Incidence rate 1.44 2.88 2.73 
Diabetes duration ≥10 years     
  Number of patients  692 875 1,144 
  Events no. 35 44 69 
  Incidence rate 3.07 2.47 2.75 
 
 
HbA1c 49-58 
mmol/mol 
HbA1c >58 
mmol/mol 
Total population  1.49 (1.09-2.05) 1.59 (1.13-2.22) 
Diabetes duration <10 years  2.38 (1.54-3.70) 2.58 (1.55-4.28) 
Diabetes duration ≥10 years  0.86 (0.55-1.35) 0.96 (0.62-1.48) 
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Figure 1. Continuous analysis of HbA1c levels and adjusted hazard ratios of 
thromboembolism stratified by diabetes duration 
 
HbA1c level was modelled with a restricted cubic spline. The applied reference value was 43 mmol/mol 
(calculated as the median HbA1c value of the reference group in the main analysis). The analysis was 
adjusted for congestive heart disease, hypertension, prior ischaemic stroke, vascular disease, sex, chronic 
kidney disease, smoking status, body mass index, age (modelled as a restricted cubic spline), statin 
treatment, antiplatelet treatment, metformin treatment, and anticoagulation treatment (as a time-varying 
covariate). Solid blue lines indicate the hazard function, and the blue shaded areas are 95% confidence 
intervals. Reproduced from Circ Arrhytm Electrophysiol. 2019;12:e007030, Copyright American Heart 
Association.   
Discussion 
In study II, we observed a dose-response pattern between increasing levels of HbA1c 
and the risk of thromboembolism in patients with a shorter duration of diabetes. In 
contrast, we observed no difference in the associated thromboembolic risk between 
the different levels of HbA1c among patients with a longer duration of diabetes. 
Recent cohort studies have sought to explore the role of glycaemic status on the risk 
of ischaemic stroke in patients with atrial fibrillation and the results have been 
conflicting. In a cohort of 37,358 patients with atrial fibrillation, Saliba et al. 
demonstrated that patients with diabetes and elevated HbA1c levels had a higher rate 
of ischaemic stroke when compared with patients without diabetes (Table 4).96 
Moreover, they observed a dose-response pattern with the rates of ischaemic stroke 
increasing across the increasing quartiles of HbA1c. Contrastingly, in a cohort of 
1,993 patients with atrial fibrillation and comorbid diabetes mellitus, Ashburner et al. 
observed that both poor (HbA1c >75 mmol/mol) and moderate (HbA1c = 53-75 
mmol/mol) glycaemic status were not significantly associated with a higher rate of 
ischaemic stroke compared with HbA1c <53 mmol/mol (Table 4).95 
In the interpretation and comparison of their findings with our observations, there are 
some essential methodological differences to consider. Firstly, our results suggest that 
the association between HbA1c level and the risk of ischaemic stroke may be modified 
by diabetes duration. In our study, the extent of this effect modification was 
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substantial as we observed a clear association between HbA1c and ischaemic stroke 
among patients with a shorter duration of diabetes and no association between HbA1c 
and ischaemic stroke among patients with a longer duration of diabetes. This finding 
suggests that it may be more appropriate to study the association between HbA1c level 
and the risk of ischaemic stroke separately for patients with shorter and longer 
duration of diabetes. Saliba et al. and Ashburner et al. presented results reflecting the 
association between hyperglycaemia and the risk of ischaemic stroke for an overall 
cohort of diabetes. In light of the observed interplay between glycaemic level and 
duration of diabetes in study II, their results may not be representative for subgroups 
of patients with different diabetes durations.  
Secondly, the reference groups varied in all three studies. In the study by Saliba et al., 
the reference group was patients without diabetes whereas Ashburner et al. used 
patients with diabetes and an HbA1c <53 mmol/mol as their reference group. In study 
II, we used a cut-point of HbA1c <48 mmol/mol as the reference group. Moreover, 
we observed that the risk of thromboembolism increased from levels of HbA1c lower 
than 53 mmol/mol among patients with shorter duration of diabetes. This may, in part, 
explain why Ashburner et al. did not find that glycaemic status was associated with 
ischaemic stroke.  
Thirdly, confounder control differed between the studies. In study II and in the study 
by Ashburner et al., the analysis was adjusted for a broad range of potential 
confounders. Saliba et al. only adjusted for the CHA2DS2-VASc score components 
which makes a direct comparison between their study and study II unfeasible.  
Fourthly, in our study we excluded patients with anaemia and chronic kidney disease 
as HbA1c measurements may be misleadingly low in these patients.122–124 Neither 
Saliba et al. or Ashburner et al. accounted for the potential misclassification bias that 
may have arisen from including these patient groups. The diabetes population in the 
study of Ashburner et al. included approximately 17% with significant kidney 
dysfunction, and as such a potential exposure misclassification cannot be viewed as a 
negligible problem.95  
Finally, neither Ashburner et al. or Saliba et al. included patients with incident atrial 
fibrillation, which may have led to an underestimation of the ischaemic stroke risk, as 
several studies show that the risk of ischaemic stroke is higher during the first year 
after an atrial fibrillation diagnosis.103–105  
In study II, we aimed to explore whether a potential aetiological relationship exists 
between glycaemic level and the risk of ischaemic stroke. Essentially, interpretation 
of an aetiological study with an observational design is challenging. The observational 
study design requires much stronger assumptions for making inference about 
causation than what is required for a randomized study design. Importantly, the 
strongest assumption (no residual or unobserved confounding) cannot be tested in an 
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observational study design, and therefore causal inference from observational studies 
is still controversial. In 1965, Austin Bradford Hill proposed nine viewpoints that may 
be taken into consideration when wishing to make causal inference based on an 
observed association.125 The observed association between HbA1c level and 
thromboembolism among patients with a shorter duration of diabetes fulfils several 
of the so called ‘Bradford Hill Criteria’:  
(1) Strength: Hill proclaimed that the larger an association between exposure and 
disease, the more likely it is to be causal. However, it is likely that most effects studied 
in the real world are small and the strength of association does not necessarily 
contribute to the determination of causality. In study II, we found a strong association 
between HbA1c level and thromboembolism among patients with a shorter duration 
of diabetes. Even so, we cannot rule out residual confounding as an explanation for 
some or the entire observed risk difference. For instance, we did not adjust for factors 
like dietary patterns and physical activity. Moreover, a large proportion of patients 
have undiagnosed diabetes126–129 and previous reports have suggested that onset of 
diabetes occurs 4-7 years before a clinical diagnosis of diabetes.130 Hence, 
discrepancies between the diabetes duration based on clinical diagnoses and the actual 
physiological duration of disease may exist. If the patients with a shorter duration of 
diabetes and a high level of HbA1c are in fact patients who have had undiagnosed 
diabetes for a longer period, then the observed results could be confounded by diabetes 
duration, despite the fact that we adjusted for the time since a clinical diabetes 
diagnosis.   
(2) Consistency: Hill stressed that a single observational study cannot be relied on to 
draw valid inference on cause and effect, as internal validity of an observational study 
is always questionable. The findings of other studies are not entirely consistent with 
the findings in study II. Several studies of patients with diabetes have shown a dose-
response relationship between glycaemic level and the risk of ischaemic stroke.117–120 
Prior studies exploring the association between HbA1c and the risk of 
thromboembolism specifically in patients with atrial fibrillation have provided 
inconsistent results.95,96 Thus, further research should focus on exploring the 
association between glycaemic level and risk of thromboembolism specifically in 
patients with atrial fibrillation. Moreover, the results of study II suggest that it may be 
reasonable to focus on potential differences of the importance of glycaemic status 
among patients with different durations of diabetes.  
(3) Specificity: the criteria of specificity covers the view that associations are more 
likely to be causal if the exposure causes only one disease. This criterion is not 
considered relevant in modern epidemiology, as many exposures are known to 
contribute to the development of several different diseases and several diseases are 
caused by a combination of exposures. The association between diabetes and the risk 
of ischaemic stroke in atrial fibrillation is undoubtedly multifactorial and by no means 
explained by glycaemic control alone.  
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(4) Temporality: the temporality criterion covers the principle that the exposure must 
precede the onset of disease and is widely accepted that this criterion is essential to 
argue causal inference. In study II, an appropriate temporal relationship existed, as the 
HbA1c level was determined prior to the development of thromboembolism.   
(5) Biological gradient: Hill argued that if a dose-response relationship is observed 
between an exposure and an effect, it is more likely to be causal. In study II, we 
observed a dose-response relationship between HbA1c level and the risk of 
thromboembolism among patients with a shorter duration of diabetes. However, we 
also observed that the thromboembolic risk attenuated at the highest levels of HbA1c 
in patients with diabetes duration <10 years. This could be an expression of a threshold 
effect of glycaemic level, where glycaemic levels above a certain threshold do not add 
additional thromboembolism risk. However, another possible explanation for this 
finding may be that these patients are more closely monitored by their physician due 
to their “uncontrolled” HbA1c level, leading to an overall better quality of oral 
anticoagulation treatment and other preventive strategies. We were unable to test this 
hypothesis, as we did not have access to information regarding quality of oral 
anticoagulation treatment or other preventive strategies.  
(6) Plausibility and (7) Coherence: these criteria covers the perception that the cause-
and-effect interrelationship should make sense with the knowledge available to the 
researcher. The results of study II could be biologically plausible as hyperglycaemia 
has been associated with several biological mechanisms that may promote 
thrombogenesis in patients with atrial fibrillation. Hyperglycaemia has been proposed 
to increase coagulability, fibrinolytic impairment, and impaired vascular 
function.131,132 Similar mechanism such as endocardial damage, endothelial 
dysfunction, platelet hyperactivity, and increased coagulability may play a role in the 
thrombogenesis in atrial fibrillation. However, the biological plausibility for the 
absence of a higher rate of ischaemic stroke in patients with a poor glycaemic status 
among the patient group with a diabetes duration ≥10 years is less clear. One 
explanation may be that thrombotic abnormalities have become manifest among 
patients with a longer duration of diabetes thereby leading to a lesser role of the 
glycaemic status. Another explanation could be that tight glycaemic control increases 
the risk of hypoglycemia especially in patients with a longer duration of disease133,134 
and hypoglycemia has been associated with a higher risk of ischaemic stroke.135 
(8) Experiment: Evidence from experimental manipulation where cessation of an 
exposure leads to a decline in disease risk has been proposed to strongly support causal 
inference. Several randomized clinical trials have investigated the effect of intensive 
glycaemic control on the risk of cardiovascular disease among patients with diabetes. 
The results have been conflicting and suggests a limited effect of tight glycaemic 
control in patients with diabetes.136 However, post-hoc analyses of these trials 
suggests a potential beneficial effect of intensive treatment among patients with a 
shorter duration of diabetes.71 Our results are in support of these findings from the 
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general diabetes cohorts, as we observed a lower risk of thromboembolism among 
patients with atrial fibrillation. However, it must be noted that the stroke mechanisms 
in atrial fibrillation are different from those in diabetes in general. Hence, the results 
of these randomized controlled trials may not be applicable to an atrial fibrillation 
population. Moreover, it must be considered that thromboembolism may be a result 
of multiple exposures and arise from a complex progression pathway. Multiple risk 
factors, including lifestyle and genetic predisposition are likely to contribute to the 
occurrence of thromboembolism. While the combination of these factors may 
culminate in disease, interventions to manipulate glycaemic levels alone may or may 
not reverse or slow the progression of thromboembolism. Thus, the observed 
associative exposure-response relationships in study II might not translate into a 
corresponding manipulative causal exposure-response relationships. In other words, 
we did not study a specific treatment approach against another and, therefore, 
randomized controlled trials evaluating the effect of specific glucose-lowering 
strategies are needed to provide conclusive evidence.137 For example, the effect of 
lowering glucose with drugs may differ from lifestyle-related interventions which are 
likely to have other beneficial health side effects.   
(9) Analogy: Bradford Hill proposed that when one causal agent is known the 
evidence needed to argue causality is lowered for a similar agent causing a similar 
disease. However, this is considered a very week criterion for causation. Moreover, 
the excessive knowledge accessible today would make it possible to identify an 
analogy for most situation.  
Even though the observed association between HbA1c and thromboembolism among 
patients with shorter duration of diabetes fulfils several of the Bradford Hill criteria, 
these viewpoints were not intended to be hard-and-fast rules of evidence to accept 
cause and effect and Hill stated that “None of the nine viewpoints can bring 
indisputable evidence for or against the cause-and-effect hypothesis”. Thus, the 
results of study II are essentially to be considered as hypothesis-generating.   
In conclusion, we demonstrated that poor glycaemic status was associated with a 
higher risk of thromboembolism in patients with atrial fibrillation and type 2 diabetes 
among patients with diabetes duration <10 years. Combining these results with prior 
findings, we conclude that the importance of glycaemic control in patients with 
diabetes and atrial fibrillation remain unclear. Hence, randomizes trials assessing 
whether strict glycaemic control would prevent thromboembolism specifically in 
patients with atrial fibrillation and type 2 diabetes are warranted.  
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CHAPTER 6. ALBUMINURIA AND 
CARDIOVASCULAR RISK IN TYPE 2 
DIABETES 
Risk stratification in patients with type 2 diabetes continues to be an important priority 
in the management of diabetes-related morbidity and mortality. Several risk factors 
have been proposed for cardiovascular risk stratification, including albuminuria.35–37 
Albuminuria is very common in patients with type 2 diabetes and around one quarter 
of patients with newly diagnosed diabetes develop microalbuminuria or nephropathy 
within ten years.138 Early albuminuria research focused primarily on 
microalbuminuria a marker for a higher risk of developing diabetic kidney disease. 
However, subjects with microalbuminuria are not necessarily destined for worse renal 
function,139,140 in fact only 25-30% of patients with microalbuminuria progress to 
chronic kidney disease.138,141,142 Contrastingly, progression of microalbuminuria into 
macroalbuminuria is most often an indication of underlying chronic kidney 
disease.138,141 Over the past two decades there has been an increased focus on 
microalbuminuria as a marker of cardiovascular disease and it is currently widely 
accepted that microalbuminuria is strongly associated with the risk of cardiovascular 
disease. The association between albuminuria levels and risk of cardiovascular disease 
has displayed a dose-response relationship142–144 that may well begin at lower levels 
than the traditional thresholds for defining microalbuminuria.141,145–147 Furthermore, 
progression of microalbuminuria has been shown to be associated with an increase in 
the risk of cardiovascular disease independent of the initial albuminuria level.138,148,149 
However, there has been less focus on micro- and macroalbuminuria as markers of 
incident cardiovascular disease in patients with type 2 diabetes.150–152 It is generally 
recognized that patients with diabetes and established cardiovascular disease are high-
risk patients that benefit from intensive treatment, hence, focus should be on 
identifying prognostic factors for cardiovascular disease among diabetes patients 
without established cardiovascular disease.35–37 Distinguishing between risk 
stratification of an incident cardiovascular event and recurrent cardiovascular events 
is necessary as risk factors may differ in their prognostic value for patients with and 
without established cardiovascular disease. Hence, we aimed to examine the 
association between micro- and macroalbuminuria and incident ischaemic stroke, 
myocardial infarction, and all-cause mortality in a nationwide cohort study of patients 
with type 2 diabetes without prevalent atherosclerotic cardiovascular disease. In the 
following section, the results of study III will be presented and discussed in relation 
to other studies that have explored the association between albuminuria and the risk 
of cardiovascular disease and mortality.  
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Results of study III 
The study population included 69,532 patients with type 2 diabetes. Incidence rates 
per 100 person-years increased in a dose-response manner across increasing levels of 
albuminuria for ischaemic stroke, myocardial infarction, and all-cause mortality 
(Table 7). Compared with patients with normoalbuminuria, we observed a higher risk 
of ischaemic stroke, myocardial infarction, and all-cause mortality among patients 
with microalbuminuria and macroalbuminuria (Table 8).  
Table 7. Crude incidence rates per 100 person-years of ischaemic stroke, myocardial 
infarction, and all-cause mortality    
 
Table 8. Hazard ratios (95% CI) of ischaemic stroke, myocardial infarction, and all-
cause mortality at 5 years follow-up (reference: normoalbuminuria)    
*Age & Sex model: adjusted for age (modelled as a restricted cubic spline) and sex. †Risk Profile model: 
Adjusted as the Age & Sex model and for systolic blood pressure, smoking status, body mass index, low-
density lipoprotein cholesterol, haemoglobin A1c, diabetes duration (modelled as a restricted cubic spline), 
congestive heart failure, and atrial fibrillation. ‡Risk & Medication Profile model: Adjusted as the Risk 
Profile model and for antiplatelet treatment, angiotensin converting enzyme inhibitors/ angiotensin-receptor 
blockers, and anticoagulation treatment.    
Outcome Normoalbuminuria 
(n = 45,695) 
Microalbuminuria 
(n = 7,254 ) 
Macroalbuminuria 
(n = 1,910) 
Ischaemic stroke    
  Events number 739 155 101 
  Incidence rate  0.39 0.59 0.90 
Myocardial infarction    
  Events number 587 129 93 
  Incidence rate  0.31 0.49 0.83 
All-cause mortality     
  Events number 2,650 690 395 
  Incidence rate  1.40 2.62 3.48 
Outcome/adjustment strategy Microalbuminuria 
(n = 7,254 ) 
Macroalbuminuria 
(n = 1,910) 
Ischaemic stroke   
  Age & Sex* 1.32 (1.11-1.57) 2.04 (1.66-2.52) 
  Risk Profile†  1.28 (1.07-1.52) 1.81 (1.46-2.23) 
  Risk & Medication Profile‡ 1.28 (1.07-1.52) 1.81 (1.46-2.24) 
Myocardial infarction   
  Age & Sex* 1.40 (1.15-1.69) 2.33 (1.87-2.90) 
  Risk Profile†  1.34 (1.10-1.62) 1.99 (1.59-2.48) 
  Risk & Medication Profile‡ 1.34 (1.11-1.63) 2.02 (1.61-2.53) 
All-cause mortality    
  Age & Sex* 1.52 (1.39-1.65) 2.03 (1.82-2.25) 
  Risk Profile† 1.48 (1.36-1.61) 1.83 (1.64-2.04) 
  Risk & Medication Profile‡ 1.49 (1.37-1.62) 1.84 (1.65-2.05) 
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Sensitivity analysis 
In a sensitivity analysis, the approach in the main analyses was repeated for the 54,859 
patients where the measurements of albuminuria were within the same albuminuria 
category. The results were similar to those from the main analysis (Table 9). 
Table 9. Hazard ratios (95% CI) of ischaemic stroke, myocardial infarction, and all-
cause mortality at five-year follow-up for 54,859 patients with consistent albuminuria 
status (reference: normoalbuminuria)    
*Age & Sex model: adjusted for age (modelled as a restricted cubic spline) and sex. †Risk Profile model: 
Adjusted as the Age & Sex model and for systolic blood pressure, smoking status, body mass index, low-
density lipoprotein cholesterol, haemoglobin A1c, diabetes duration (modelled as a restricted cubic spline), 
congestive heart failure, and atrial fibrillation. ‡Risk & Medication Profile model: Adjusted as the Risk 
Profile model and for antiplatelet treatment, angiotensin converting enzyme inhibitors/ angiotensin-receptor 
blockers, and anticoagulation treatment.    
Discussion  
The results of study III show that both micro- and macroalbuminuria are risk markers 
for incident ischaemic stroke, incident myocardial infarction, and all-cause mortality 
in patients with type 2 diabetes without established cardiovascular disease. This 
finding is in line with the findings of several longitudinal observational studies that 
have assessed the association between albuminuria level and the risk of atherosclerotic 
cardiovascular disease and all-cause mortality among patients with type 2 diabetes 
(Table 10). These studies have unanimously showed that patients with increased 
levels of albuminuria had a higher risk of atherosclerotic cardiovascular events. Study 
III build upon these prior findings by focusing specifically on patients with type 2 
diabetes and no established cardiovascular disease. The studies by Fung et al. and 
Chen et al. also limited their study population to patients without cardiovascular 
disease. However, extrapolation of results from Asian populations to a Scandinavian 
population may not be applicable as ethnic differences in risk of cardiovascular 
disease exist, which may relate to differences in gene-environment interactions and 
genetic susceptibility.153   
Outcome/adjustment strategy Microalbuminuria 
(n = 7,254 ) 
Macroalbuminuria 
(n = 1,910) 
Ischaemic stroke   
  Age & Sex* 1.35 (1.11-1.63) 2.45 (1.91-3.16) 
  Risk Profile†  1.31 (1.09-1.59) 2.06 (1.59-2.67) 
  Risk & Medication Profile‡ 1.32 (1.09-1.60) 2.07 (1.60-2.69) 
Myocardial infarction   
  Age & Sex* 1.44 (1.17-1.77) 2.96 (2.29-3.82) 
  Risk Profile†  1.39 (1.13-1.71) 2.39 (1.84-3.10) 
  Risk & Medication Profile‡ 1.40 (1.13-1.72) 2.43 (1.87-3.17) 
All-cause mortality    
  Age & Sex* 1.56 (1.42-1.72) 2.70 (2.38-3.06) 
  Risk Profile† 1.52 (1.38-1.67) 2.39 (2.10-2.72) 
  Risk & Medication Profile‡ 1.53 (1.39-1.68) 2.41 (2.11-2.74) 
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A key limitation in current literature is the categorisation of albuminuria level. Of the 
twelve studies in Table 10 that explored albuminuria and the risk of either 
cardiovascular disease or cardiovascular mortality, nine studies based their 
albuminuria categorisation on a single albuminuria measurement. As the day to day 
variation of urinary albuminuria excretion is substantial this approach may lead to 
exposure misclassification bias.154,155 Although, Svensson et al. based their 
categorisation of albuminuria on the presence of micro- or macroalbuminuria in at 
least two out of three samples, the categorisation of the exposure in their study was 
assessed by the individual physician’s and as such the researchers did not have access 
to the actual measurements of albuminuria.156 This limits the validity of their exposure 
classification significantly. Chen et al. and Targher et al. assessed the UACR in two 
and three consecutive samples, respectively.157 The approach by Targher et al. is in 
line with current recommendations for the classification of albuminuria which require 
that micro- or macroalbuminuria should be present in two of three specimens within 
a 3 to 6-month period.158 In study III, we were unable to apply that specific definition 
of albuminuria as we were limited by the data obtained through the registries. The 
Danish Adult Diabetes Registry contains data from annual diabetes check-ups, these 
annual check-ups are sometimes delayed a few months. Thus, to retrieve two 
consecutive measurements of UACR or UAE, we broadened the criteria to up to 15 
months between two consecutive tests.  
Both albuminuria and low estimated glomerular filtration rate (eGFR) are indicators 
of kidney decline and the Kidney Disease: Improving Global Outcomes organization  
guidelines state that the categorization of chronic kidney disease should be based on 
both the eGFR and the level of albuminuria.159 As chronic kidney disease is a known 
risk factor for cardiovascular disease,160 exploring both albuminuria and eGFR as 
markers of a higher risk of cardiovascular disease and all-cause mortality is a 
reasonable approach. However, data completeness is very limited for measurements 
of eGFR in the Danish Adult Diabetes Registry, which prohibited us from exploring 
the association between eGFR and the risk of cardiovascular disease. Several of the 
aforementioned studies have, however, explored the role of eGFR in predicting 
cardiovascular disease and all-cause mortality. These studies have provided 
conflicting results regarding the association between eGFR and the risk of 
cardiovascular disease.  Some studies found no associations between baseline eGFR 
and the risk of cardiovascular events when adjusting for known cardiovascular risk 
factors.151,152,161 Whereas other studies showed that lower levels of eGFR were 
associated with a higher risk of experiencing a cardiovascular event.142,144,156 The 
findings are more consistent for all-cause mortality where several studies have shown 
that decreasing eGFR was associated with a higher risk of all-cause 
mortality.142,144,157,162 Furthermore, it has been suggested that combining albuminuria 
and eGFR leads to improved accuracy in predicting cardiovascular risk and all-cause 
mortality.150 Nevertheless, several studies have shown that micro- and macro-
albuminuria at baseline were associated with a higher risk of cardiovascular event, 
regardless of eGFR status.156,161,163 Hence, current literature suggest that albuminuria 
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may be a better predictor of cardiovascular disease compared to eGFR. This finding 
may be explained by albuminuria not only reflecting kidney function, but also a 
generalized abnormality of the vascular function. Although the mechanisms linking 
microalbuminuria to cardiovascular disease are not fully understood, a common 
pathophysiologic process involving endothelial dysfunction, chronic low-grade 
inflammation, and increased transvascular leakiness of albumin is believed to play a 
role.164 It has been suggested that endothelial dysfunction heightens the atherogenic 
state, thereby increasing the risk of atherosclerotic cardiovascular disease and 
microalbuminuria may reflect this endothelial dysfunction.165–168 Others have 
suggested that the association is simply explained by common underlying risk factors 
between microalbuminuria and cardiovascular disease. Nonetheless, several of the 
studies listed in Table 10 have found albuminuria to be associated with cardiovascular 
disease and all-cause mortality independent of other know cardiovascular risk factors. 
It should be emphasized that the spectrum of cardiovascular risk factors remains to be 
discovered fully. Hence, a hitherto undiscovered risk factor for the development of 
cardiovascular disease that is related with microalbuminuria could theoretically 
explain the link. However, we adjusted for a broad variety of known risk factors and 
still found a strong association between albuminuria and cardiovascular risk, hence, it 
would seem unlikely that other, yet undiscovered, risk factors would explain the 
association fully.  
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Table 10. Risk estimates for clinical outcomes according to albuminuria status 
reported in longitudinal observational studies of patients with type 2 diabetes  
Author, year No. of 
patients 
Albuminuria 
level 
HR 95% CI 
Outcome: Cardiovascular event, n = 8 
Bouchi et al., 
2010169 
 
1,002 UACR <30 mg/g 
UACR: 30-299 mg/g 
UACR ≥300 mg/g 
1 
2.33 
3.70 
(Reference) 
(1.52-3.57) 
(2.21-6.23) 
Chen et al., 
2012151 
487* 
 
UACR <30 mg/g 
UACR: 30-299.9 mg/g 
1 
1.61 
(Reference) 
(0.75-3.44) 
Miettinen et al., 
1996170 
 
1,056 UACR <150 mg/l 
UACR: 150-299 mg/l  
UACR ≥300 mg/l 
1 
1.30 
2.16 
(Reference) 
(1.00-2.07) 
(1.51-3.09) 
Fung et al., 
2017150 
 
67,334* 
 
Normoalbuminuria 
UACR >2.5 mg/mmol 
UACR >3.5 mg/mmol 
UACR >25 mg/mmol 
UACR >25 mg/mmol 
      1 (reference) 
   1.58 (male) 
   1.48 (female) 
   2.57 (male) 
   2.40 (female) 
 
Monseu et al., 
2015144  
1,371 Albuminuria (log UACR) 1.33 (1.13-1.56) 
Svensson et al., 
2013156 
66,065 UAE <20 μg/min 
UAE: 20-200 μg/min 
UAE >200 μg/min 
1 
1.16 
1.36 
(Reference) 
(1.09-1.23) 
(1.25-1.47) 
Viana et al., 
2012171 
199 UACR <30 mg/g 
UACR ≥30 mg/g 
1 
2.89 
(Reference) 
(1.29-6.45) 
Wada et al., 
2013163  
 
4,328 UACR <30 mg/g 
UACR: 30-299 mg/g 
UACR ≥300 mg/g 
1  
1.38 
2.05 
(Reference) 
(1.14-1.67) 
(1.61-2.58) 
Outcome: Cardiovascular mortality, n = 5 
Bruno et al., 
2007172 
1,538 UAE <20 μg/min 
UAE: 20-200 μg/min 
UAE >200 μg/min 
1  
1.06 
2.00 
(Reference) 
(0.80-1.40) 
(1.48-2.71) 
Cox et al., 2013142  1,220 1 SD increment in UACR 1.47 (1.24-1.74) 
Monseu et al., 
2015144  
1,371 Albuminuria (log 
mg/mmol) 
1.46 (1.20-1.77) 
Targher et al., 
2011157  
2,823 UACR <30 mg/g 
UACR: 30-299 mg/g 
UACR ≥300 mg/g 
1 
1.56 
3.40 
(Reference) 
(0.85-3.1) 
(1.50-7.80) 
Valmadrid et al., 
2000173  
840  UACR <30 mg/g 
UACR: 30-299.9 mg/l 
UACR ≥300 mg/l 
1 
1.84 
2.61  
(Reference) 
(1.42-2.40) 
(1.99-3.43) 
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Table 10 -continued 
Outcome: All-cause mortality, n = 12 
Berhane et al., 
2011174  
2,420 UACR <30 mg/g†  
UACR: 30-299 mg/g† 
UACR ≥300 mg/g† 
 1 
2.0 
2.5  
(Reference) 
(1.3-3.0) 
(1.8-3.43) 
Bruno et al., 
2007172  
1,538 UAE <20 μg/min 
UAE: 20-200 μg/min 
UAE >200 μg/min 
1 
1.30 
1.91 
(Reference) 
(1.08-1.57) 
(1.54-2.38) 
Cox et al., 2013142  1,220 1 SD increment in UACR 1.41 (1.25-1.59) 
Chen et al., 
2012151  
487 UACR <30 mg/g 
UACR: 30-299.9 mg/g 
1 
1.80 
(Reference) 
(0.71-4.56) 
Fung et al.  
2017150 
67,334 Normoalbuminuria 
UACR >2.5 mg/mmol 
UACR >3.5 mg/mmol 
UACR >25 mg/mmol 
UACR >25 mg/mmol 
      1 (Reference) 
    2.08 (Male) 
    1.78 (Female) 
    4.36 (Male) 
    3.07 (Female) 
Miyake et al., 
2018175 
385 Logarithm of UAE 1.32 (1.02-1.07) 
Monseu et al., 
2015144  
1,371 Albuminuria (log UACR) 1.38 (1.19-1.59) 
Murussi et al., 
2007176  
173 UAE <5μg/min 
UAE >5μg/min 
1 
2.70 
(Reference) 
(1.20-6.10) 
Tanaka et al., 
2015162    
3,231   1 SD increment in log 
UACR 
1.31 (0.99-1.72) 
Targher et al., 
2011157  
2,833 UACR <30 mg/g 
UACR: 30-299 mg/g 
UACR ≥300 mg/g 
1  
1.17 
2.86 
(Reference) 
(0.73-1.90) 
(1.60-5.00) 
Viana et al., 
2012171  
199 UACR <30 mg/g 
UACR ≥30 mg/g 
1 
5.07 
(reference) 
(1.01-24.88) 
Wada et al., 
2014163  
4,328 UACR <30 mg/g 
UACR: 30-299 mg/g 
UACR ≥300 mg/g 
1  
1.37 
3.60 
(reference) 
(0.99-1.89) 
(2.53-5.20) 
*Population without overt cardiovascular disease at inclusion. †eGFR = 90-119 ml/min per. 1.73. UACR: 
urinary albumin-to-creatinine ratio, UAE: urinary albumin excretion rate, SD: standard deviation, CI: 
confidence interval.  
 
The 2016 guidelines from the ESC on cardiovascular disease prevention management 
recommend high intensity statin treatment for patients with type 2 diabetes at very 
high risk of cardiovascular disease, defined as a 10-year cardiovascular risk of more 
than 10%.47 The 2019 guidelines from ADA on cardiovascular disease and risk 
management state that it may be appropriate with intensive lipid lowering for 
individuals with a 10-year cardiovascular risk of ≥20%.35 Similarly, several guidelines 
state that aspirin may be considered in the context of high atherosclerotic 
cardiovascular risk with low bleeding risk.35,177 In study III, both micro- and 
macroalbuminuria were associated with increased risk of cardiovascular disease and 
using albuminuria status in combination with other well-known cardiovascular risk 
markers may provide the basis for identifying patients with diabetes and a 10-year risk 
of 10-20% in whom intensive vascular risk reduction is currently advocated for.35,47 
However, the effect of intensive interventions in people with type 2 diabetes and 
microalbuminuria has yet to be established. In the Steno-2 randomized trial, lower 
mortality and lower incidence of cardiovascular events were observed when 
comparing an intensified multifactorial treatment including aspirin treatment and 
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intensified glycaemic control, lipid lowering, and blood pressure control to 
conventional treatment in patients with type 2 diabetes and microalbuminuria.178 This 
may suggest a beneficial effect of intensified treatment in patients with type 2 diabetes 
and microalbuminuria. Nonetheless, a recent meta-analysis including the Steno-2 
randomized trial and two subgroups from other randomized trials did not provide 
conclusive evidence to support that intensive multifactorial intervention reduces the 
risk of stroke, myocardial infarction, cardiovascular mortality, or all-cause 
mortality.179 Hence, it is unclear whether the presence of microalbuminuria in patients 
with type 2 diabetes should result in intensified treatment. Similarly, it is unclear 
whether reducing albuminuria translates into a reduction in long-term development of 
cardiovascular disease and mortality. A meta-analysis found that pharmacological 
blockade of angiotensin II receptors was effective in reducing the risk of new-onset 
albuminuria in patients with type 2 diabetes. However, the study was unable to show 
a significant reduction in mortality.180 Nonetheless, in patients with diabetes and 
nephropathy reducing albuminuria appears to be protective for the development of 
cardiovascular disease.181 Hence, based on the current literature it is not clear whether 
microalbuminuria is an actual therapeutic target in itself.   
In conclusion, the results of study III clearly indicate that micro- and 
macroalbuminuria are robust markers of increased risk of cardiovascular events. 
Using albuminuria status in combination with other well-known cardiovascular risk 
markers may provide the basis for clinically useful cardiovascular risk assessment 
among patients with diabetes and no established cardiovascular disease. 
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CHAPTER 7. METHODOLOGICAL 
CONSIDERATIONS 
The overall aim of an epidemiological study is to obtain estimates of the frequency of 
an outcome or the effect of a given exposure on the outcome that are both accurate 
and precise. Obtaining both accuracy and precision of an estimated result requires 
minimal error in the estimation process. Errors can emerge through study design, 
conduct, and analysis. Often errors are separated into systematic and random error and 
whereas random error leads to loss of precision, systematic error may lead to loss of 
accuracy of the results. Accuracy of results are often referred to as the validity, and 
epidemiological studies are evaluated both on internal and external validity. Whereas 
internal validity raises the question of whether the results of a given study is true for 
the population studied, or an artefact of the way the study was designed, external 
validity raises the question of whether the study results are likely to apply to an 
external target population. Thus, internal validity is a prerequisite for external 
validity.182 Internal validity of a cohort study can be threatened by systematic errors, 
also known as bias. Traditionally, bias is divided into selection bias, information bias, 
and confounding. In the following paragraphs, issues concerning selection bias, 
information bias, confounding, external validity, and random error in study I-III, will 
be discussed.  
 
Selection bias occurs when the association between the exposure and the disease 
differs between those who are in the study and those who are not.183 Selection bias 
can be introduced by the processes that leads to the overall loss of study population 
throughout the study. Thus, it can stem from the process of selecting the initial study 
population or from differential loss to follow-up or censoring during the study.   
Selection of the study population  
In study I and as a partial inclusion criterion in study II, the study populations were 
identified based on a first-time hospital diagnosis of atrial fibrillation in the Danish 
National Patients Registry. A diagnosis of atrial fibrillation has been found to have a 
high validity in the Danish National Patient Registry and validation studies have 
estimated the positive predictive value to range between 92-99%.184–186 Thus, it is 
reasonable to assume that the vast majority of patients included in study I and II do in 
fact have atrial fibrillation. However, the sensitivity of a diagnosis of the atrial 
fibrillation in the Danish National Patient Registry has not been assessed. Thus, we 
have no estimate of the proportion of patients with incident atrial fibrillation we have 
actually captured during the inclusion period. Nevertheless, Danish guidelines 
recommend referring patients with newly diagnosed atrial fibrillation to a specialist 
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evaluation, and as such, it is likely that we captured the vast majority of patents with 
incident atrial fibrillation during the inclusion period.     
All studies in this dissertation focused on patients with diabetes. However, patients 
with diabetes were identified with different criteria in the three studies. In study I, we 
identified patients with type 1 or type 2 diabetes by using an algorithm that relied on 
hospital-based diagnoses and claimed prescription drugs. This identification method 
made us unable to identify patients with diabetes managed exclusively in general 
practice who were solely receiving non-pharmacological treatment. Non-
pharmacologically managed patients with type 2 diabetes are likely to be those with 
the lowest prevalence of cardiovascular risk factors. We did not adjust for all potential 
risk factors for ischaemic stroke, as the study aimed to explore the type of diabetes as 
an easily obtainable proxy for the differences in the distribution of those very same 
cardiovascular risk factors. Therefore, we may have induced selection bias as we may 
have compared high-risk type 2 diabetes patients with type 1 diabetes patients.   
In Study II and III, patients with type 2 diabetes were identified through the Danish 
Adult Diabetes Registry. The data completeness from outpatient clinics is high in the 
Danish Adult Diabetes Registry, whereas the data completeness from primary care is 
considerably lower.65 As the majority of patients with type 2 diabetes are treated in 
primary health care we did not capture the entire population of patients with type 2 
diabetes in Denmark. Patients followed in secondary care are likely to have a higher 
burden of comorbidities and therefore our population are likely to be a high-risk 
population compared with the general diabetes population. Furthermore, in study II, 
we excluded patients who did not have an available HbA1c measurements within two 
years before the index date. This led to an exclusion of a large number of patients. 
These patients were generally younger and had a lower burden of comorbidity. In 
study III, we only included patients with two measurements of microalbuminuria 
within 15 months before the index date. Therefore, we did not capture all patients with 
diabetes during the study period. Hence, this population may be a high-risk population 
with more comorbidities than the general diabetes population which may have 
resulted in rates of ischaemic stroke that are higher than those of the general Danish 
diabetes population.  
Nonetheless, selection bias is only induced when the association between the given 
exposures and the outcome differs between those who are included and those who are 
not. It is not likely that the association between glycaemic status/microalbuminuria 
and ischaemic stroke differs between those who were included and those who were 
not. Thus, the above-mentioned limitations in the selection of the study population are 
not expected to induce actual selection bias in study II and III and thereby threaten the 
internal validity of the study. Instead these limitations in the selection of the study 
populations can raise the question of the generalizability of the results to a target 
population.  
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Censoring  
Loss to follow-up and losses due to competing risk can be handled with censoring in 
survival analysis such as the Cox regression analysis. Survival analysis relies on the 
independent censoring assumption which is that the censoring must be unrelated to 
the risk of the outcome within each exposure group. In other words, those who are 
censored should not be individuals with systematically higher or lower risk of the 
outcome compared to the individuals who remains at risk.  
In study I-III, patients were followed in The Danish National Patient Registry for the 
outcomes under study and aside from a few patients emigrating during the study 
period this led to almost complete follow-up. A potential problematic cause of 
censoring was performed in study I where patients were censored when initiating 
anticoagulation treatment. In order to comply with the independent censoring 
assumption, patients initiating anticoagulation treatment needs to be a random subset 
of the population, this may not be the case. Therefore, censoring may be informative 
with respect to the outcome. As initiation of anticoagulation treatment was more 
frequent among patients with type 2 diabetes, this may have led to an underestimation 
of risk specifically among patients with type 2 diabetes as compared with type 1 
diabetes. 
In all studies, death was considered a competing risk for the other outcomes. Due to 
the register-based nature of the datasets, deaths can be categorised into two main 
categories; i) deaths that are due to undiagnosed cardiovascular events that otherwise 
would have been defined as an outcome, had they been diagnosed. These patients 
were censored but should really have been registered as having the outcome under 
study, and ii) deaths unrelated to the cardiovascular events of interest, which are the 
only deaths that are considered to be actual competing events. We were unable to 
make this distinction, since causes of death are poorly recorded in Danish registries; 
only 4% of people dying have an autopsy performed.187 In a high mortality population 
like the diabetes population, some patients die from other causes before experiencing 
the outcome of interest. If the exposure is associated with a higher risk of death than 
the outcome of interest, it may lead to an overestimation of the association between 
the exposure and the outcome. In study III, the risk of all-cause mortality was higher 
among those with micro- and macroalbuminuria thereby potentially violating the 
independent censoring assumption. Moreover, it is likely that the exposures in study 
I and II, in a similar fashion, would increase the risk of death and thereby violate the 
independent censoring assumption. Nonetheless, one could argue that estimating 
associations between exposures and outcomes in a high mortality population where 
patients do not die belongs to a hypothetical world. By analysing associations with a 
cause specific Cox regression model, as we did in our studies, inference for disease 
rates are made in the presence of the competing risk of dying.70  
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When information used in a study is erroneous, for example, due to incorrect 
measuring or classification of study variables (exposures, outcomes, and 
confounders/risk factors), it can lead to information bias.15 When information bias 
leads to subjects being placed in an incorrect exposure or outcome category, it is 
denoted as misclassification bias. Misclassification can be differential or 
nondifferential. Nondifferential misclassification is a misclassification unrelated to 
other study variables and it leads to more predictable bias and will often affect the 
estimates towards the null. Differential misclassification occurs when the 
misclassified variable is related to other variables in the study and it leads to more 
unpredictable bias. Study outcomes were identified through the Danish National 
Patient Registry and as such is depended on the accuracy of the diagnoses in this 
registry. Incomplete or inaccurate registration can lead to information bias. 
Exposure misclassification 
In study I, patients with type 1 diabetes were compared with patients with type 2 
diabetes in respect to the risk of thromboembolism. To classify patients as having 
either type 1 or type 2 diabetes, we used a combination of ICD-10 codes and 
information on claimed prescriptions of glucose-lowering drugs. This classification 
of patients can have induced misclassification bias – e.g., a patient with type 2 diabetes 
receiving monotherapy with insulin who is not registered with an ICD-10 code of type 
2 diabetes or has an erroneous ICD-10 code of type 1 diabetes would be misclassified 
as a patient with type 1 diabetes. Furthermore, after the initial classification of 
patients, there was approximately 24% of patients classified as having type 1 diabetes 
that were receiving oral glucose lowering drugs.105 This was likely a misclassification 
of patients with type 2 diabetes as type 1 diabetes patients. We addressed this potential 
error in a sensitivity analysis where these patients were relocated to the type 2 diabetes 
group. The analysis resulted in similar estimates as in the main analysis.      
In study II, the exposure was glycaemic status as reflected by the measured HbA1c 
level. The HbA1c measurements were captured directly from the electronic medical 
record systems, which minimized the risk of data entry errors and thereby minimized 
misclassification bias. Patients were classified according to their baseline level of 
HbA1c defined as the most recent HbA1c measurement within the past two years 
before or the first four weeks after inclusion. Using up to two years old HbA1c 
measurements may have led to misclassification as patients’ HbA1c measurements 
can change during this time period. In a sensitivity analysis we assessed whether using 
a more recent HbA1c measurement, obtained within one year before or the first four 
weeks after inclusion, would affect the results. This analysis resulted in similar 
estimates as the main analysis and thereby it supports the validity of our main findings. 
However, the potential effects of glycaemia on the risk of developing ischaemic stroke 
is presumably due to a long-term exposure to heightened levels of glucose, and we 
did not account for variations in glycaemic control over longer periods prior to 
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inclusion - nor did we account for the potential changes in HbA1c during follow-up. 
As it is unrealistic to assume that HbA1c values remain stable throughout this period 
of time, making inferences regarding the effect of glycaemic control on 
thromboembolic risk based on one static HbA1c value is questionable. Thus, we only 
examined the association between the risk of ischaemic stroke and glycaemic status, 
but not glycaemic control.  
In study III, the exposure was albuminuria level. As the biological variability in 
urinary albumin excretion is substantial, we used two consecutive measurements of 
albuminuria to minimize misclassification bias. Moreover, we observed that some 
patients did not have a consistent categorization in their two measurements, therefore 
we performed a sensitivity analyses restricted to patients with a consistent 
categorization of albuminuria in both measurements. The sensitivity analysis resulted 
in similar results as the main analysis. To categorize albuminuria, measurements of 
either UACR or UAE were used. Both these measurements have been shown to have 
a high sensitivity and specificity for the detection of albuminuria. Moreover, exposure 
misclassification due to imprecise measurements is unlikely to be systematic and 
would therefore tend to draw associations towards the null.  
Outcome misclassification  
The results in all three studies consisted of a measure of event rates and HR’s of the 
outcomes. Potential misclassification of the outcomes affects these measures 
differently. Whereas the HR’s are primarily susceptible to bias if the misclassification 
is differential; event rates based on administrative data can be altered substantially 
depending on the extent and validity of the diagnoses used to define the outcome.  
Often, an outcome can be defined by several diagnoses in the registries that more or 
less precisely captures patients with the actual outcome under study. Generally, a 
broad definition of an outcome leads to loss of specificity and will tend to overestimate 
event rates. Oppositely, a narrow definition leads to loss of sensitivity and will tend 
to underestimate the event rates. In all studies, ischaemic stroke was an outcome. This 
outcome was defined as a combination of ischaemic stroke and unspecified stroke. 
Using a diagnosis of unspecified stroke to define the outcome may have misclassified 
some patients as having had an ischaemic stroke when in fact they had that actually 
had a haemorrhagic stroke. Thus, including unspecified stroke in the definition of the 
outcome in all studies has likely led to an overestimation of the event rates. 
Nonetheless, most strokes coded as unspecific have been reported to be of ischaemic 
origin and as such we viewed it to be reasonable to include unspecified stroke in the 
outcome definition.188 Furthermore, refraining from including these patients would 
most likely led to an underestimation of the event rates.  
Another concern that may affect the observed event rates, is whether the outcome is 
defined by primary diagnoses only or by a combination of primary and secondary 
diagnoses. Secondary diagnoses are more likely to be an expression of an old event 
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(carry-over diagnosis) and will therefore tend to overestimate the event rates, whereas 
including only primary diagnoses may underestimate the event rates. As we only used 
primary diagnoses in our studies, we may have underestimated the event rates.  
The validity of the individual diagnostic codes will also affect how precisely the 
outcomes are estimated. If the diagnostic code of an outcome has a low positive 
predictive value that will tend to overestimate the event rates, whereas a low 
sensitivity will tend to underestimate the event rates. In our studies, ischaemic stroke 
and acute myocardial infarction were some of the outcomes under study and the 
validity of a primary diagnoses of those diseases in the Danish National Patient 
Registry have been shown to be high, with positive predictive values of 81% and 97%, 
respectively.189,190 
As previously mentioned, some patients may have died due to an unrecognized 
ischaemic stroke or myocardial infarction. By not being able to capture these patients 
we may have underestimated the ‘true’ risk of ischaemic stroke and myocardial 
infarction. If death due to ischaemic stroke and myocardial infarction had been 
included in the outcomes it would have resulted in more precise event rate estimates.  
As described, there are various sources of potential errors when estimating the rates 
of ischaemic stroke and myocardial infarction through administrative registries. It is 
not possible to determine the sum of all these errors. We must merely conclude that 
the event rates have been estimated with errors and must be interpreted with caution. 
Nonetheless, the above-mentioned sources of information bias are not expected to be 
related to the exposures in study I-III, and as such a potential misclassification of the 
outcomes are expected to drive the HR estimates towards the null. Therefore 
misclassification bias is not expected to be the explanation for the observed 
differences in the rates of the outcomes.  
Comorbidity misclassification 
The comorbidity status of the individual patients was obtained through the registries. 
Thus, the precision with which we captured the actual comorbidity status of these 
patients depends on the validity of diagnoses and prescriptions in the registries. As 
the validity of these diagnoses vary,189 some degree of misclassification of the 
comorbidity status of the study population occurred in all three studies. For variables 
obtained through the Danish Adult Diabetes Registry, we identified a varying degree 
of missing data. We handled missing variables with the ‘missing indicator’ method in 
study II and III. However, this method may have induced some degree of bias as data 
in the registries probably are not missing completely at random.191   
Medication misclassification  
The baseline medication status of the study cohorts was ascertained through the 
Danish National Prescription Registry which holds information regarding claimed 
prescriptions. Therefore, the information in the registries are only reflecting the 
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medications that have been claimed, which may not equal the medication that have 
been consumed. If there are differences in the compliance to the medication in the 
different exposure groups it may have led to differential misclassification bias. 
Another concern is the quality of treatment with anticoagulation treatment, 
specifically with vitamin k antagonist treatment. As we did not have access to 
information regarding international normalized ratio (INR) values, we do not know 
the time in therapeutic range for the patients receiving vitamin k antagonists. This 
may have led to residual confounding in study II.   
 
Confounding is defined as a confusion of effects. It occurs when the primary exposure 
of interest is mixed up with some other factor that causes the outcome under study. A 
confounder is a factor that is associated with the exposure of interest and a cause of 
the outcome under study. A confounder cannot be an intermediary step that lie on the 
causal pathway between the exposure and the outcome. Confounding as a concept is 
by definition only an issue in studies of aetiology where the objective is to determine 
the causal effect of an exposure on the outcome. Controlling for confounding is 
essential in aetiological studies and it can be performed with statistical modelling. 
Nonetheless, confounder control strategies are usually imperfect in cohort studies as 
a confounder may be measured imperfectly, modelled incorrectly, or be unavailable 
in the applied data. Study II was an aetiological study and therefore we adjusted for a 
wide range of potential confounders. However, as discussed in Chapter 5, the 
observational study design makes us unable to rule out residual confounding as part 
of the observed results.  
 
So far potential sources of systematic errors have been described. Another source of 
error is random error. Random error is unexplained variation in the data. Generally, 
reducing random error and thereby increasing the precision of an estimate can be 
achieved by increasing the study size. In all three studies, the sample sizes were 
relatively high with an accompanying high number of outcomes, allowing for precise 
effect estimates with reasonable narrow CIs. 
 
External validity, also denoted generalisability, refers to the extent to which an 
internally valid result in a study sample can be extrapolated to the target population. 
To make meaningful inference about the generalizability of the results of a study to a 
target population, the target population must be well-defined. Thus, whether the aim 
is to generalize the results to the population from which the sample population was 
derived or to an entirely different population will affect the extent to which the results 
are generalizable. Our studies comprised a reasonable large sample of the individual 
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populations that we view as our target populations in Denmark. However, as described 
previously, the selection into the study may have resulted in a high-risk study 
population in study II and III. This may limit the generalizability of the results. 
Furthermore, when generalizing our results to other populations it must be taken into 
account that the Danish population is ethnically non-diverse. Therefore, the results 
may not apply in more ethnically diverse populations. 
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CHAPTER 8. CONCLUSIONS AND 
PERSPECTIVES 
The prevalence of diabetes has been and continues to be on the rise and the future 
burden of diabetes-related cardiovascular disease is likely to increase. Hence, a 
continued focus on cardiovascular disease prevention is paramount. The studies of 
this dissertation contributes to the identification of a number of risk factors for 
ischaemic stroke and myocardial infarction both in a general cohort of patients with 
diabetes and in patients with diabetes and concomitant atrial fibrillation. Identifying 
high- and low-risk subgroups in the diabetes population may provide the basis for 
evidence-based clinical risk stratification that may serve as a valuable clinical tool in 
aiding clinical counselling of patients and guiding treatment decisions.  
We explored whether the type of diabetes and glycaemic status were associated with 
a higher risk of thromboembolism in patients with diabetes and atrial fibrillation. We 
found that overall, the type of diabetes was not associated with a higher risk of 
thromboembolism, while type 2 diabetes was associated with a substantially higher 
risk of ischaemic stroke in the subgroup of patients aged below 65 years.  Furthermore, 
the results suggested that increasing levels of glycaemic status are associated with a 
higher risk of thromboembolism in patients with a shorter duration diabetes, but not 
in patients with a longer duration of diabetes. In study I and II, the association between 
the exposures and the outcomes were modified by age and diabetes duration, 
respectively. These findings underline the complexity of risk stratification in diabetes 
and atrial fibrillation.  Our findings may indicate that type 2 diabetes is associated 
with a higher risk of thromboembolism among patients under 65 years and that poor 
glycaemic status is associated with a higher risk of thromboembolism among patients 
with a shorter duration of diabetes. However, studies investigating these specific 
exposures are limited and the role of both type of diabetes and glycaemic status in 
patients with diabetes and atrial fibrillation remains unclear. Hence, future studies are 
necessary to confirm our findings. Study I and II provides a perspective on how risk 
stratification in atrial fibrillation and diabetes could potentially be improved, however, 
there is currently no basis to support a subdivision of diabetes patients according to 
diabetes-related factors. Hence, diabetes should continue to be incorporated into the 
CHA2DS2-VASc score as an entity. Furthermore, both prior studies and the findings 
of our studies indicate that patients with atrial fibrillation and concomitant diabetes 
carry a high risk of ischaemic stroke and are therefore likely to benefit from 
anticoagulation treatment.  
We also explored whether micro- and macroalbuminuria are associated with incident 
ischaemic stroke, myocardial infarction, and all-cause mortality among patients with 
type 2 diabetes without overt cardiovascular disease. We found that micro- and 
macroalbuminuria are robust markers of a higher risk of cardiovascular events. Hence, 
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the presence of micro- or macroalbuminuria should warrant careful evaluation of 
cardiovascular risk among patients with diabetes and considerations of suitable 
preventive strategies, due to the observed higher risk of cardiovascular events. Future 
studies may focus on including albuminuria status in combination with other well-
known cardiovascular risk markers to develop cardiovascular risk stratification tools 
to identify high-risk diabetes patients that may benefit from intensified preventive 
strategies.   
The observational nature of the studies in this dissertation makes us unable to 
conclude whether the identified high-risk groups of this dissertation may directly 
benefit from intensified treatment. Ultimately, randomized controlled trials 
investigating the effect of intensified treatment among high-risk groups are needed to 
provide conclusive evidence. However, currently such trials are either not available 
or have provided inconsistent results and until additional evidence from randomized 
controlled trials emerge, cohort studies detecting differences in risk profiles in 
subpopulations of diabetes patients should continue to inform and aid clinicians in 
their decision making. 
 
 
63 
 
 
REFERENCES 
1 Esundhed.dk [Internet]. 
http://esundhed.dk/sundhedsregistre/uks/uks01/Sider/Tabel.aspx. . 
2 Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates 
of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin 
Pract 2018;138:271–281. 
3 Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of 
diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4–14. 
4 Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes 
prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 
2014;103:137–149. 
5 Leslie RD, Palmer J, Schloot NC, et al. Diabetes at the crossroads: relevance 
of disease classification to pathophysiology and treatment. Diabetologia 
2016;59:13–20. 
6 Scheen AJ. Pathophysiology of type 2 diabetes. Acta Clin Belg 2003;58:335–
341. 
7 Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from 
pathophysiology to prevention and management. Lancet (London, England) 
2011;378:169–181. 
8 Chobot A, Gorowska-Kowolik K, Sokolowska M, et al. Obesity and diabetes-
Not only a simple link between two epidemics. Diabetes Metab Res Rev 
2018;34:e3042. 
9 Stancakova A, Laakso M. Genetics of Type 2 Diabetes. Endocr Dev 
2016;31:203–220. 
10 Zimmet PZ, Magliano DJ, Herman WH, et al. Diabetes: a 21st century 
challenge. lancet Diabetes Endocrinol 2014;2:56–64. 
11 Maahs DM, West NA, Lawrence JM, et al. Epidemiology of type 1 diabetes. 
Endocrinol Metab Clin North Am 2010;39:481–497. 
12 Baena-Diez JM, Penafiel J, Subirana I, et al. Risk of Cause-Specific Death in 
Individuals With Diabetes: A Competing Risks Analysis. Diabetes Care 
DIABETES MELLITUS AND CARDIOVASCULAR DISEASE 
64 
 
2016;39:1987–1995. 
13 Seuring T, Archangelidi O, Suhrcke M. The Economic Costs of Type 2 
Diabetes: A Global Systematic Review. Pharmacoeconomics 2015;33:811–
831. 
14 Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev 
1999;15:205–218. 
15 Schram MT, Baan CA, Pouwer F. Depression and quality of life in patients 
with diabetes: a systematic review from the European depression in diabetes 
(EDID) research consortium. Curr Diabetes Rev 2009;5:112–119. 
16 Reid DD, Brett GZ, Hamilton PJ, et al. Cardiorespiratory disease and diabetes 
among middle-aged male Civil Servants. A study of screening and 
intervention. Lancet (London, England) 1974;1:469–473. 
17 Eastman RC, Keen H. The impact of cardiovascular disease on people with 
diabetes: the potential for prevention. Lancet (London, England) 1997;350 
Suppl:SI29-32. 
18 Ducimetiere P, Eschwege E, Papoz L, et al. Relationship of plasma insulin 
levels to the incidence of myocardial infarction and coronary heart disease 
mortality in a middle-aged population. Diabetologia 1980;19:205–210. 
19 Pyorala K. Relationship of glucose tolerance and plasma insulin to the 
incidence of coronary heart disease: results from two population studies in 
Finland. Diabetes Care 1979;2:131–141. 
20 Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes 
mellitus, fasting blood glucose concentration, and risk of vascular disease: a 
collaborative meta-analysis of 102 prospective studies. Lancet 
2010;375:2215–2222. 
21 Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al. Diabetes mellitus, 
fasting glucose, and risk of cause-specific death. N Engl J Med 
2011;364:829–841. 
22 Scherer PE, Hill JA. Obesity, Diabetes, and Cardiovascular Diseases: A 
Compendium. Circ. Res. 2016;118:1703–1705. 
23 James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients 
with acute coronary syndromes and diabetes: a substudy from the PLATelet 
inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010;31:3006–
REFERENCES 
 
65 
 
3016. 
24 Cavender MA, Scirica BM, Bonaca MP, et al. Vorapaxar in patients with 
diabetes mellitus and previous myocardial infarction:  findings from the 
thrombin receptor antagonist in secondary prevention of atherothrombotic 
ischemic events-TIMI 50 trial. Circulation 2015;131:1047–1053. 
25 Yeap BB, McCaul KA, Flicker L, et al. Diabetes, myocardial infarction and 
stroke are distinct and duration-dependent predictors of subsequent 
cardiovascular events and all-cause mortality in older men. J Clin Endocrinol 
Metab 2015;100:1038–1047. 
26 Icks A, Claessen H, Morbach S, et al. Time-dependent impact of diabetes on 
mortality in patients with stroke: survival up to 5 years in a health insurance 
population cohort in Germany. Diabetes Care 2012;35:1868–1875. 
27 Kamalesh M, Shen J, Eckert GJ. Long term postischemic stroke mortality in 
diabetes: a veteran cohort analysis. Stroke 2008;39:2727–2731. 
28 Tanaka R, Ueno Y, Miyamoto N, et al. Impact of diabetes and prediabetes on 
the short-term prognosis in patients with acute ischemic stroke. J Neurol Sci 
2013;332:45–50. 
29 Tziomalos K, Spanou M, Bouziana SD, et al. Type 2 diabetes is associated 
with a worse functional outcome of ischemic stroke. World J Diabetes 
2014;5:939–944. 
30 Nomura S. Dynamic role of microparticles in type 2 diabetes mellitus. Curr 
Diabetes Rev 2009;5:245–251. 
31 Pomero F, Di Minno MN, Fenoglio L, et al. Is diabetes a hypercoagulable 
state? A critical appraisal. Acta Diabetol 2015;52:1007–1016. 
32 Bulugahapitiya U, Siyambalapitiya S, Sithole J, et al. Is diabetes a coronary 
risk equivalent? Systematic review and meta-analysis. Diabet Med 
2009;26:142–148. 
33 Wong ND, Glovaci D, Wong K, et al. Global cardiovascular disease risk 
assessment in United States adults with diabetes. Diabetes Vasc Dis Res 
2012;9:146–152. 
34 Ford ES. Trends in the risk for coronary heart disease among adults with 
diagnosed diabetes in the U.S.: findings from the National Health and 
Nutrition Examination Survey, 1999-2008. Diabetes Care 2011;34:1337–
DIABETES MELLITUS AND CARDIOVASCULAR DISEASE 
66 
 
1343. 
35 10. Cardiovascular Disease and Risk Management: Standards of Medical 
Care in Diabetes-2019. Diabetes Care 2019;42:S103–S123. 
36 Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on 
the Primary Prevention of Cardiovascular Disease. Circulation 
2019;:CIR0000000000000678. 
37 Members AF, Ryden L, Grant PJ, et al. ESC Guidelines on diabetes, pre-
diabetes, and cardiovascular diseases developed in collaboration with the 
EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases 
of the European Society of Cardiology (ESC) and developed in collaboratio. 
Eur Heart J 2013;34:3035–3087. 
38 Collaborative overview of randomised trials of antiplatelet therapy--I: 
Prevention of death, myocardial infarction, and stroke by prolonged 
antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ 
Collaboration. BMJ 1994;308:81–106. 
39 Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary 
prevention of vascular disease: collaborative meta-analysis of individual 
participant data from randomised trials. Lancet (London, England) 
2009;373:1849–1860. 
40 Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of 
perindopril and indapamide on macrovascular and microvascular outcomes in 
patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised 
controlled trial. Lancet (London, England) 2007;370:829–840. 
41 Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-
pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575–
1585. 
42 Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function 
independently predict cardiovascular and renal outcomes in diabetes. J Am 
Soc Nephrol 2009;20:1813–1821. 
43 Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering 
therapy in 18,686 people with diabetes in 14 randomised trials of statins: a 
meta-analysis. Lancet (London, England) 2008;371:117–125. 
44 Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin 
Therapy after Acute Coronary Syndromes. N Engl J Med 2015;372:2387–
REFERENCES 
 
67 
 
2397. 
45 Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid 
lowering with statins after acute coronary syndromes. N Engl J Med 
2004;350:1495–1504. 
46 Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical 
Outcomes in Patients with Cardiovascular Disease. N Engl J Med 
2017;376:1713–1722. 
47 Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on 
cardiovascular disease prevention in clinical practice: The Sixth Joint Task 
Force of the European Society of Cardiology and Other Societies on 
Cardiovascular Disease Prevention in Clinical Practice (constituted by 
representati. Atherosclerosis 2016;252:207–274. 
48 Tun NN, Arunagirinathan G, Munshi SK, et al. Diabetes mellitus and stroke: 
A clinical update. World J Diabetes 2017;8:235–248. 
49 Larsson SC, Scott RA, Traylor M, et al. Type 2 diabetes, glucose, insulin, 
BMI, and ischemic stroke subtypes: Mendelian randomization study. 
Neurology 2017;89:454–460. 
50 Tsai C-F, Anderson N, Thomas B, et al. Risk factors for ischemic stroke and 
its subtypes in Chinese vs. Caucasians: Systematic review and meta-analysis. 
Int J Stroke 2015;10:485–493. 
51 Morillo CA, Banerjee A, Perel P, et al. Atrial fibrillation: the current 
epidemic. J Geriatr Cardiol 2017;14:195–203. 
52 Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, 
and predisposing conditions for atrial fibrillation: population-based estimates. 
Am J Cardiol 1998;82:2N-9N. 
53 Smith JG, Platonov PG, Hedblad B, et al. Atrial fibrillation in the Malmo Diet 
and Cancer study: a study of occurrence, risk factors and diagnostic validity. 
Eur J Epidemiol 2010;25:95–102. 
54 Naccarelli G V, Varker H, Lin J, et al. Increasing prevalence of atrial 
fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534–
1539. 
55 Huxley RR, Filion KB, Konety S, et al. Meta-analysis of cohort and case-
control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J 
DIABETES MELLITUS AND CARDIOVASCULAR DISEASE 
68 
 
Cardiol 2011;108:56–62. 
56 Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of 
antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five 
randomized controlled trials. Arch Intern Med 1994;154:1449–1457. 
57 Hart RG, Pearce LA, McBride R, et al. Factors associated with ischemic 
stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants 
in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation 
(SPAF) Investigators. Stroke 1999;30:1223–1229. 
58 Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or 
death in individuals with new-onset atrial fibrillation in the community: the 
Framingham Heart Study. JAMA 2003;290:1049–1056. 
59 Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the 
management of atrial fibrillation developed in collaboration with EACTS. Eur 
Heart J 2016;37:2893–2962. 
60 Thygesen LC, Daasnes C, Thaulow I, et al. Introduction to Danish 
(nationwide) registers on health and social issues: structure, access, 
legislation, and archiving. Scand J Public Health 2011;39:12–16. 
61 Pedersen CB. The Danish Civil Registration System. Scand J Public Health 
2011;39:22–25. 
62 Schmidt M, Schmidt SAJ, Sandegaard JL, et al. The Danish National Patient 
Registry: a review of content, data quality, and research potential. Clin 
Epidemiol 2015;:449. 
63 Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription 
Registry. Scand J Public Health 2011;39:38–41. 
64 Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. 
Scand J Public Health 2011;39:30–33. 
65 Jorgensen ME, Kristensen JK, Reventlov Husted G, et al. The Danish Adult 
Diabetes Registry. Clin Epidemiol 2016;8:429–434. 
66 Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System 
as a tool in epidemiology. Eur J Epidemiol 2014;29:541–549. 
67 Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, et al. Data Resource 
Profile: The Danish National Prescription Registry. Int J Epidemiol 
REFERENCES 
 
69 
 
2017;46:798-798f. 
68 Authority DHD. Algorithm for selected chronic diseses and severe mental 
disorders. [Internet]. ;2017.Available from: 
http//www.esundhed.dk/sundhedsregistre/uks/Documents/Algoritmer for 
RUKS.PDF. 
69 McGuire H, Longson D, Adler A, et al. Management of type 2 diabetes in 
adults: summary of updated NICE guidance. BMJ 2016;353:i1575. 
70 Andersen PK, Geskus RB, de Witte T, et al. Competing risks in epidemiology: 
possibilities and pitfalls. Int J Epidemiol 2012;41:861–870. 
71 Brown A, Reynolds LR, Bruemmer D. Intensive glycemic control and 
cardiovascular disease: an update. Nat Rev Cardiol 2010;7:369–375. 
72 Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of 
stroke in patients with atrial fibrillation: a systematic review. Neurology 
2007;69:546–554. 
73 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to 
prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern 
Med 2007;146:857–867. 
74 Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and 
safety of new oral anticoagulants with warfarin in patients with atrial 
fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–962. 
75 Lip GYH, Laroche C, Ioachim PM, et al. Prognosis and treatment of atrial 
fibrillation patients by European cardiologists: One Year Follow-up of the 
EURObservational Research Programme-Atrial Fibrillation General Registry 
Pilot Phase (EORP-AF Pilot registry). Eur Heart J 2014. 
doi:10.1093/eurheartj/ehu374. 
76 Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation 
in seven European countries after the publication of the 2010 ESC Guidelines 
on atrial fibrillation: primary results of the PREvention oF thromboemolic 
events--European Registry in Atrial Fibrillation (PREFER in AF). Europace 
2014;16:6–14. 
77 Sulzgruber P, Wassmann S, Semb AG, et al. Oral Anticoagulation in patients 
with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 - a 
current opinion of the European Society of Cardiology Working Group on 
Cardiovascular Pharmacotherapy and European Society of Cardiology 
DIABETES MELLITUS AND CARDIOVASCULAR DISEASE 
70 
 
Council on St. Eur Hear journal Cardiovasc Pharmacother 2019. 
doi:10.1093/ehjcvp/pvz016. 
78 Joundi RA, Cipriano LE, Sposato LA, et al. Ischemic Stroke Risk in Patients 
With Atrial Fibrillation and CHA2DS2-VASc Score of 1: Systematic Review 
and Meta-Analysis. Stroke 2016;:STROKEAHA.115.012609. 
79 Nielsen PB, Chao T-F. The risks of risk scores for stroke risk assessment in 
atrial fibrillation. Thromb Haemost 2015;113:1170–1173. 
80 McCormick N, Bhole V, Lacaille D, et al. Validity of diagnostic codes for 
acute stroke in administrative databases: a systematic review. PLoS One 
2015;10:e0135834. 
81 Nielsen PB, Larsen TB, Skjøth F, et al. Stroke and thromboembolic event 
rates in atrial fibrillation according to different guideline treatment thresholds: 
A nationwide cohort study. Sci Rep 2016;6:27410. 
82 Eckman MH, Singer DE, Rosand J, et al. Moving the tipping point: the 
decision to anticoagulate patients with atrial fibrillation. Circ Qual outcomes 
2011;4:14–21. 
83 Dzeshka MS, Gill PS, Lip GYH. Cardiovascular risk prediction: balancing 
complexity against simple practicality. Br. J. Gen. Pract. 2015;65:4–5. 
84 Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification 
schemes for predicting stroke and thromboembolism in patients with atrial 
fibrillation: nationwide cohort study. BMJ 2011;342:d124. 
85 van den Ham HA, Klungel OH, Singer DE, et al. Comparative Performance 
of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in 
Patients With Atrial Fibrillation: Results From a National Primary Care 
Database. J Am Coll Cardiol 2015;66:1851–1859. 
86 Van Staa TP, Setakis E, Di Tanna GL, et al. A comparison of risk stratification 
schemes for stroke in 79,884 atrial fibrillation patients in general practice. J 
Thromb Haemost 2011;9:39–48. 
87 Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for 
predicting stroke and thromboembolism in atrial fibrillation using a novel risk 
factor-based approach: the euro heart survey on atrial fibrillation. Chest 
2010;137:263–272. 
88 Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes 
REFERENCES 
 
71 
 
for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: 
the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33:1500–1510. 
89 Singer DE, Chang Y, Borowsky LH, et al. A new risk scheme to predict 
ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA 
study stroke risk score. J Am Heart Assoc 2013;2:e000250. 
90 Proietti M, Boriani G, Laroche C, et al. Self-reported physical activity and 
major adverse events in patients with atrial fibrillation: a report from the 
EURObservational Research Programme Pilot Survey on Atrial Fibrillation 
(EORP-AF) General Registry. Europace 2017;19:535–543. 
91 Overvad TF, Rasmussen LH, Skjoth F, et al. Body mass index and adverse 
events in patients with incident atrial fibrillation. Am J Med 2013;126:640.e9-
640.17. 
92 Wang HJ, Si QJ, Shan ZL, et al. Effects of body mass index on risks for 
ischemic stroke, thromboembolism, and mortality in Chinese atrial fibrillation 
patients: a single-center experience. PLoS One 2015;10:e0123516. 
93 Qi Z, Chen H, Wen Z, et al. Relation of Low-Density Lipoprotein Cholesterol 
to Ischemic Stroke in Patients With Nonvalvular Atrial Fibrillation. Am J 
Cardiol 2017;119:1224–1228. 
94 Overvad TF, Skjoth F, Lip GY, et al. Duration of Diabetes Mellitus and Risk 
of Thromboembolism and Bleeding in Atrial Fibrillation: Nationwide Cohort 
Study. Stroke 2015;46:2168–2174. 
95 Ashburner JM, Go AS, Chang Y, et al. Effect of Diabetes and Glycemic 
Control on Ischemic Stroke Risk in AF Patients: ATRIA Study. J Am Coll 
Cardiol 2016;67:239–247. 
96 Saliba W, Barnett-Griness O, Elias M, et al. Glycated hemoglobin and risk of 
first episode stroke in diabetic patients with atrial fibrillation: A cohort study. 
Hear Rhythm 2015;12:886–892. 
97 Chou AY, Liu C-J, Chao T-F, et al. Presence of diabetic microvascular 
complications does not incrementally increase  risk of ischemic stroke in 
diabetic patients with atrial fibrillation: A nationwide cohort study. Medicine 
(Baltimore) 2016;95:e3992. 
98 Lip GYH, Clementy N, Pierre B, et al. The impact of associated diabetic 
retinopathy on stroke and severe bleeding risk in diabetic patients with atrial 
fibrillation: the loire valley atrial fibrillation project. Chest 2015;147:1103–
DIABETES MELLITUS AND CARDIOVASCULAR DISEASE 
72 
 
1110. 
99 Patti G, Lucerna M, Cavallari I, et al. Insulin-Requiring Versus Noninsulin-
Requiring Diabetes and Thromboembolic Risk in Patients With Atrial 
Fibrillation: PREFER in AF. J Am Coll Cardiol 2017;69:409–419. 
100 Fangel MV, Nielsen PB, Kristensen JK, et al. Glycemic Status and 
Thromboembolic Risk in Patients With Atrial Fibrillation and  Type 2 
Diabetes Mellitus. Circ Arrhythm Electrophysiol 2019;12:e007030. 
101 Mentias A, Shantha G, Adeola O, et al. Role of diabetes and insulin use in the 
risk of stroke and acute myocardial infarction in patients with atrial 
fibrillation: A Medicare analysis. Am Heart J 2019;214:158–166. 
102 The International Federation of Clinical Chemistry Working Group (IFCC-
WG). International Federation of Clinical Chemistry (IFCC) Standardization 
of HbA1c. Available from: http://www.ngsp.org/docs/IFCCstd.pdf. 
103 Frost L, Engholm G, Johnsen S, et al. Incident stroke after discharge from the 
hospital with a diagnosis of atrial fibrillation. Am J Med 2000;108:36–40. 
104 Wolf PA, Kannel WB, McGee DL, et al. Duration of atrial fibrillation and 
imminence of stroke: the Framingham study. Stroke 1983;14:664–667. 
105 Fangel M V, Nielsen PB, Larsen TB, et al. Type 1 versus type 2 diabetes and 
thromboembolic risk in patients with atrial fibrillation: A Danish nationwide 
cohort study. Int J Cardiol 2018;268:137–142. 
106 Overvad TF. Stroke risk stratification in atrial fibrillation. The CHA2DS 2 -
VASc score and beyond. 2016.Available from: 
https://vbn.aau.dk/ws/portalfiles/portal/240986452/PHD_Thure_Filskov_Ov
ervad_E_pdf.pdf. 
107 Kim SJ, Ryoo S, Kwon S, et al. Is atrial fibrillation always a culprit of stroke 
in patients with atrial fibrillation plus stroke? Cerebrovasc Dis 2013;36:373–
382. 
108 Bogousslavsky J, Van Melle G, Regli F, et al. Pathogenesis of anterior 
circulation stroke in patients with nonvalvular atrial fibrillation: the Lausanne 
Stroke Registry. Neurology 1990;40:1046–1050. 
109 Tuttolomondo A, Pinto A, Salemi G, et al. Diabetic and non-diabetic subjects 
with ischemic stroke: differences, subtype distribution and outcome. Nutr 
Metab Cardiovasc Dis 2008;18:152–157. 
REFERENCES 
 
73 
 
110 Pinto A, Tuttolomondo A, Di Raimondo D, et al. A case control study 
between diabetic and non-diabetic subjects with ischemic stroke. Int Angiol 
2007;26:26–32. 
111 Austin PC, Steyerberg EW. Predictive accuracy of risk factors and markers: 
a simulation study of the effect of novel markers on different performance 
measures for logistic regression models. Stat Med 2013;32:661–672. 
112 van Doorn S, Debray TPA, Kaasenbrood F, et al. Predictive performance of 
the CHA2DS2-VASc rule in atrial fibrillation: a systematic review and meta-
analysis. J Thromb Haemost 2017;15:1065–1077. 
113 D’Agostino RB. Risk prediction and finding new independent prognostic 
factors. J. Hypertens. 2006;24:643–645. 
114 Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current 
status, and future directions. Circulation 2010;121:1768–1777. 
115 Banerjee A, Mathew D, Rouane K. Using patient data for patients’ benefit. 
BMJ. 2017;358:j4413. 
116 Chao TF, Liu CJ, Wang KL, et al. Should Atrial Fibrillation Patients With 
One Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex) 
Receive Oral Anticoagulation? J Am Coll Cardiol 2015;65:635–642. 
117 Selvin E, Coresh J, Shahar E, et al. Glycaemia (haemoglobin A1c) and 
incident ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC) 
Study. The LancetNeurology 2005;4:821–826. 
118 Zhang Y, Hu G, Yuan Z, et al. Glycosylated hemoglobin in relationship to 
cardiovascular outcomes and death in patients with type 2 diabetes: a 
systematic review and meta-analysis. PLoS One 2012;7:e42551. 
119 Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated 
hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 
2004;141:421–431. 
120 Andersson C, van Gaal L, Caterson ID, et al. Relationship between HbA1c 
levels and risk of cardiovascular adverse outcomes and all-cause mortality in 
overweight and obese cardiovascular high-risk women and men with type 2 
diabetes. Diabetologia 2012;55:2348–2355. 
121 Boden-Albala B, Cammack S, Chong J, et al. Diabetes, fasting glucose levels, 
and risk of ischemic stroke and vascular events: findings from the Northern 
DIABETES MELLITUS AND CARDIOVASCULAR DISEASE 
74 
 
Manhattan Study (NOMAS). Diabetes Care 2008;31:1132–1137. 
122 Hoshino J, Molnar MZ, Yamagata K, et al. Developing an HbA(1c)-based 
equation to estimate blood glucose in maintenance hemodialysis patients. 
Diabetes Care 2013;36:922–927. 
123 Nagayama H, Inaba M, Okabe R, et al. Glycated albumin as an improved 
indicator of glycemic control in hemodialysis patients with type 2 diabetes 
based on fasting plasma glucose and oral glucose tolerance test. Biomed 
Pharmacother 2009;63:236–240. 
124 English E, Idris I, Smith G, et al. The effect of anaemia and abnormalities of 
erythrocyte indices on HbA1c analysis: a systematic review. Diabetologia 
2015;58:1409–1421. 
125 HILL AB. The Environment and Disease: Association Or Causation? Proc R 
Soc Med 1965;58:295–300. 
126 Selvin E, Wang D, Lee AK, et al. Identifying Trends in Undiagnosed Diabetes 
in U.S. Adults by Using a Confirmatory Definition: A Cross-sectional Study. 
Ann Intern Med 2017;167:769–776. 
127 Heidemann C, Du Y, Paprott R, et al. Temporal changes in the prevalence of 
diagnosed diabetes, undiagnosed diabetes and prediabetes: findings from the 
German Health Interview and Examination Surveys in 1997-1999 and 2008-
2011. Diabet Med 2016;33:1406–1414. 
128 Moody A, Cowley G, Ng Fat L, et al. Social inequalities in prevalence of 
diagnosed and undiagnosed diabetes and impaired glucose regulation in 
participants in the Health Surveys for England series. BMJ Open 
2016;6:e010155. 
129 Heltberg A, Andersen JS, Sandholdt H, et al. Predictors of undiagnosed 
prevalent type 2 diabetes - The Danish General Suburban Population Study. 
Prim Care Diabetes 2018;12:13–22. 
130 Harris MI, Klein R, Welborn TA, et al. Onset of NIDDM occurs at least 4-7 
yr before clinical diagnosis. Diabetes Care 1992;15:815–819. 
131 Pechlivani N, Ajjan RA. Thrombosis and Vascular Inflammation in Diabetes: 
Mechanisms and Potential Therapeutic Targets. Front Cardiovasc Med 
2018;5:1. 
132 Mather KJ. The vascular endothelium in diabetes--a therapeutic target? Rev 
REFERENCES 
 
75 
 
Endocr Metab Disord 2013;14:87–99. 
133 Lipska KJ, Warton EM, Huang ES, et al. HbA1c and risk of severe 
hypoglycemia in type 2 diabetes: the Diabetes and Aging Study. Diabetes 
Care 2013;36:3535–3542. 
134 Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic 
control versus targeting conventional glycaemic control for type 2 diabetes 
mellitus. Cochrane database Syst Rev 2013;(11):CD008. 
doi:10.1002/14651858.CD008143.pub3 [doi]. 
135 Smith L, Chakraborty D, Bhattacharya P, et al. Exposure to hypoglycemia and 
risk of stroke. Ann N Y Acad Sci;https://do. doi:10.1111/nyas.13872 [doi]. 
136 Buehler AM, Cavalcanti AB, Berwanger O, et al. Effect of tight blood glucose 
control versus conventional control in patients with type 2 diabetes mellitus: 
a systematic review with meta-analysis of randomized controlled trials. 
Cardiovasc Ther 2013;31:147–160. 
137 Hernan MA. Does water kill? A call for less casual causal inferences. Ann 
Epidemiol 2016;26:674–680. 
138 Adler AI, Stevens RJ, Manley SE, et al. Development and progression of 
nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes 
Study (UKPDS 64). Kidney Int 2003;63:225–232. 
139 Molitch ME, Steffes M, Sun W, et al. Development and progression of renal 
insufficiency with and without albuminuria in adults with type 1 diabetes in 
the diabetes control and complications trial and the epidemiology of diabetes 
interventions and complications study. Diabetes Care 2010;33:1536–1543. 
140 Bakris GL, Molitch M. Microalbuminuria as a risk predictor in diabetes: the 
continuing saga. Diabetes Care 2014;37:867–875. 
141 Effects of ramipril on cardiovascular and microvascular outcomes in people 
with diabetes mellitus: results of the HOPE study and MICRO-HOPE 
substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 
(London, England) 2000;355:253–259. 
142 Cox AJ, Hsu F-C, Carr JJ, et al. Glomerular filtration rate and albuminuria 
predict mortality independently from coronary artery calcified plaque in the 
Diabetes Heart Study. Cardiovasc Diabetol 2013;12:68. 
143 Perkovic V, Verdon C, Ninomiya T, et al. The relationship between 
DIABETES MELLITUS AND CARDIOVASCULAR DISEASE 
76 
 
proteinuria and coronary risk: a systematic review and meta-analysis. PLoS 
Med 2008;5:e207. 
144 Monseu M, Gand E, Saulnier P-J, et al. Acute Kidney Injury Predicts Major 
Adverse Outcomes in Diabetes: Synergic Impact  With Low Glomerular 
Filtration Rate and Albuminuria. Diabetes Care 2015;38:2333–2340. 
145 Danziger J. Importance of low-grade albuminuria. Mayo Clin Proc 
2008;83:806–812. 
146 Li M-F, Tu Y-F, Li L-X, et al. Low-grade albuminuria is associated with early 
but not late carotid atherosclerotic lesions in community-based patients with 
type 2 diabetes. Cardiovasc Diabetol 2013;12:110. 
147 Huang Y, Chen Y, Xu M, et al. Low-grade albuminuria is associated with 
carotid intima-media thickness in Chinese type 2 diabetic patients. J Clin 
Endocrinol Metab 2010;95:5122–5128. 
148 Spoelstra-de Man AM, Brouwer CB, Stehouwer CD, et al. Rapid progression 
of albumin excretion is an independent predictor of cardiovascular mortality 
in patients with type 2 diabetes and microalbuminuria. Diabetes Care 
2001;24:2097–2101. 
149 Yuyun MF, Dinneen SF, Edwards OM, et al. Absolute level and rate of 
change of albuminuria over 1 year independently predict mortality and 
cardiovascular events in patients with diabetic nephropathy. Diabet Med 
2003;20:277–282. 
150 Fung CSC, Wan EYF, Chan AKC, et al. Association of estimated glomerular 
filtration rate and urine albumin-to-creatinine ratio with incidence of 
cardiovascular diseases and mortality in chinese patients with type 2 diabetes 
mellitus - a population-based retrospective cohort study. BMC Nephrol 
2017;18:47. 
151 Chen Y-H, Chen H-S, Tarng D-C. More impact of microalbuminuria on 
retinopathy than moderately reduced GFR among  type 2 diabetic patients. 
Diabetes Care 2012;35:803–808. 
152 Zhang X-L, Yuan M-X, Wan G, et al. The effects of AER and eGFR on 
outcomes of CVD in patients with T2DM in an urban  community over 8 years 
of multifactorial treatment: the Beijing Communities Diabetes Study 18. Ther 
Clin Risk Manag 2018;14:1537–1545. 
153 Gazzola K, Reeskamp L, van den Born B-J. Ethnicity, lipids and 
REFERENCES 
 
77 
 
cardiovascular disease. Curr Opin Lipidol 2017;28:225–230. 
154 Smulders YM, Slaats EH, Rakic M, et al. Short-term variability and sampling 
distribution of various parameters of urinary albumin excretion in patients 
with non-insulin-dependent diabetes mellitus. J Lab Clin Med 1998;132:39–
46. 
155 Phillipou G, Phillips PJ. Variability of urinary albumin excretion in patients 
with microalbuminuria. Diabetes Care 1994;17:425–427. 
156 Svensson MK, Cederholm J, Eliasson B, et al. Albuminuria and renal function 
as predictors of cardiovascular events and mortality in a general population of 
patients with type 2 diabetes: a nationwide observational study from the 
Swedish National Diabetes Register. Diabetes Vasc Dis Res 2013;10:520–
529. 
157 Targher G, Zoppini G, Chonchol M, et al. Glomerular filtration rate, 
albuminuria and risk of cardiovascular and all-cause  mortality in type 2 
diabetic individuals. Nutr Metab Cardiovasc Dis 2011;21:294–301. 
158 11. Microvascular Complications and Foot Care: Standards of Medical Care 
in Diabetes-2019. Diabetes Care 2019;42:S124–S138. 
159 Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and 
prognosis of chronic kidney disease: a KDIGO Controversies Conference 
report. Kidney Int 2011;80:17–28. 
160 Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and 
albuminuria for prediction of cardiovascular outcomes: a collaborative meta-
analysis of individual participant data. lancet Diabetes Endocrinol 
2015;3:514–525. 
161 Yokoyama H, Araki S, Haneda M, et al. Chronic kidney disease categories 
and renal-cardiovascular outcomes in type 2 diabetes without prevalent 
cardiovascular disease: a prospective cohort study (JDDM25). Diabetologia 
2012;55:1911–1918. 
162 Tanaka N, Babazono T, Takagi M, et al. Albuminuria and reduced glomerular 
filtration rate for predicting the renal outcomes in type 2 diabetic patients. 
Nephrology (Carlton) 2015;20:531–538. 
163 Wada T, Haneda M, Furuichi K, et al. Clinical impact of albuminuria and 
glomerular filtration rate on renal and cardiovascular events, and all-cause 
mortality in Japanese patients with type 2 diabetes. Clin Exp Nephrol 
DIABETES MELLITUS AND CARDIOVASCULAR DISEASE 
78 
 
2014;18:613–620. 
164 Stehouwer CDA, Smulders YM. Microalbuminuria and risk for 
cardiovascular disease: Analysis of potential mechanisms. J Am Soc Nephrol 
2006;17:2106–2111. 
165 Jensen JS, Borch-Johnsen K, Jensen G, et al. Microalbuminuria reflects a 
generalized transvascular albumin leakiness in clinically healthy subjects. 
Clin Sci (Lond) 1995;88:629–633. 
166 Kalaitzidis RG, Bakris GL. Serum creatinine vs. albuminuria as biomarkers 
for the estimation of cardiovascular risk. Curr Vasc Pharmacol 2010;8:604–
611. 
167 Khosla N, Sarafidis PA, Bakris GL. Microalbuminuria. Clin Lab Med 
2006;26:635–653, vi–vii. 
168 Viberti GC, Jarrett RJ, McCartney M, et al. Increased glomerular permeability 
to albumin induced by exercise in diabetic subjects. Diabetologia 
1978;14:293–300. 
169 Bouchi R, Babazono T, Yoshida N, et al. Association of albuminuria and 
reduced estimated glomerular filtration rate with incident stroke and coronary 
artery disease in patients with type 2 diabetes. Hypertens Res 2010;33:1298–
1304. 
170 Miettinen H, Haffner SM, Lehto S, et al. Proteinuria predicts stroke and other 
atherosclerotic vascular disease events in nondiabetic and non-insulin-
dependent diabetic subjects. Stroke 1996;27:2033–2039. 
171 Viana LV, Gross JL, Camargo JL, et al. Prediction of cardiovascular events, 
diabetic nephropathy, and mortality by albumin concentration in a spot urine 
sample in patients with type 2 diabetes. J Diabetes Complications 
2012;26:407–412. 
172 Bruno G, Merletti F, Bargero G, et al. Estimated glomerular filtration rate, 
albuminuria and mortality in type 2 diabetes: the Casale Monferrato study. 
Diabetologia 2007;50:941–948. 
173 Valmadrid CT, Klein R, Moss SE, et al. The risk of cardiovascular disease 
mortality associated with microalbuminuria and gross proteinuria in persons 
with older-onset diabetes mellitus. Arch Intern Med 2000;160:1093–1100. 
174 Berhane AM, Weil EJ, Knowler WC, et al. Albuminuria and estimated 
REFERENCES 
 
79 
 
glomerular filtration rate as predictors of diabetic end-stage renal disease and 
death. Clin J Am Soc Nephrol 2011;6:2444–2451. 
175 Miyake H, Kanazawa I, Sugimoto T. Albuminuria Increases All-Cause 
Mortality in Japanese Patients with Type 2 Diabetes Mellitus. J Clin Med 
2018;7. doi:10.3390/jcm7090234. 
176 Murussi M, Campagnolo N, Beck MO, et al. High-normal levels of 
albuminuria predict the development of micro- and macroalbuminuria and 
increased mortality in Brazilian Type 2 diabetic patients: an 8-year follow-up 
study. Diabet Med 2007;24:1136–1142. 
177 Patti G, Cavallari I, Andreotti F, et al. Prevention of atherothrombotic events 
in patients with diabetes mellitus: from antithrombotic therapies to new-
generation glucose-lowering drugs. Nat Rev Cardiol 2019;16:113–130. 
178 Gaede P, Oellgaard J, Carstensen B, et al. Years of life gained by 
multifactorial intervention in patients with type 2 diabetes mellitus and 
microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. 
Diabetologia 2016;59:2298–2307. 
179 Usman M, Gillies CL, Khunti K, et al. Effects of intensive interventions 
compared to standard care in people with type  2 diabetes and 
microalbuminuria on risk factors control and cardiovascular outcomes: A 
systematic review and meta-analysis of randomised controlled trials. Diabetes 
Res Clin Pract 2018;146:76–84. 
180 Persson F, Lindhardt M, Rossing P, et al. Prevention of microalbuminuria 
using early intervention with renin-angiotensin system inhibitors in patients 
with type 2 diabetes: A systematic review. J Renin Angiotensin Aldosterone 
Syst 2016;17. doi:10.1177/1470320316652047. 
181 de Zeeuw D, Remuzzi G, Parving H-H, et al. Albuminuria, a therapeutic target 
for cardiovascular protection in type 2 diabetic patients with nephropathy. 
Circulation 2004;110:921–927. 
182 Rothman KJ, Greenland S, Lash TL. Modern Epidemiology, 3rd ed. 
Philadelphia: Lippincott Williams & Wilkins, 2008. 
183 Rothman KJ. Epidemiology : an introduction, 2nd ed. New York: Oxford 
University Presss, 2012. 
184 Frost L, Vestergaard P. Alcohol and risk of atrial fibrillation or flutter: a 
cohort study. Arch Intern Med 2004;164:1993–1998. 
DIABETES MELLITUS AND CARDIOVASCULAR DISEASE 
80 
 
185 Rix TA, Riahi S, Overvad K, et al. Validity of the diagnoses atrial fibrillation 
and atrial flutter in a Danish patient registry. Scand Cardiovasc J 
2012;46:149–153. 
186 Frost L, Andersen LV, Vestergaard P, et al. Trend in mortality after stroke 
with atrial fibrillation. Am J Med 2007;120:47–53. 
187 Ylijoki-Sorensen S, Boldsen JL, Lalu K, et al. Cost-consequence analysis of 
cause of death investigation in Finland and in Denmark. Forensic Sci Int 
2014;245:133–142. 
188 Krarup L-H, Boysen G, Janjua H, et al. Validity of stroke diagnoses in a 
National Register of Patients. Neuroepidemiology 2007;28:150–154. 
189 Sundboll J, Adelborg K, Munch T, et al. Positive predictive value of 
cardiovascular diagnoses in the Danish National Patient Registry: a validation 
study. BMJ Open 2016;6:e012832-2016–012832. 
190 Luhdorf P, Overvad K, Schmidt EB, et al. Predictive value of stroke discharge 
diagnoses in the Danish National Patient Register. Scand J Public Health 
2017;45:630–636. 
191 Groenwold RHH, White IR, Donders ART, et al. Missing covariate data in 
clinical research: when and when not to use the missing-indicator method for 
analysis. CMAJ 2012;184:1265–1269. 
 
81 
 
APPENDICES 
 
Appendix A: Algorithm for identification of type 1 and type 2 diabetes  
 
Appendix B: Paper I 
 
Appendix C: Paper II 
 
Appendix D: Paper III 

 
83 
 
APPENDIX A. ALGORITHM FOR 
IDENTIFICATION OF TYPE 1 AND TYPE 
2 DIABETES  
Algorithm developed by the Danish Health Data Authority for identifying type 1 and 
type 2 diabetes patients based on Danish register data from the Danish National 
Patient Registry and the Danish National Prescription Registry.   
 
Algorithm for identification of Type 2 diabetes 
Inclusion:  
• Persons with a minimum of one prescription claim of glucose lowering drugs (ATC 
code: A10B) with exclusion of insulin or insulin analogues (ATC code: A10A) in 
the Danish National Prescription Registry. 
• Persons with a relevant primary or secondary diagnosis (ICD-10 code: E11) as the 
last of specific diagnoses (ICD-10 code: E10 and E11) in the Danish National 
Patient Registry. 
 
Exclusion: 
• Persons who are solely registered the Danish National Prescription Registry with 
one claimed prescription of insulin or insulin analogues (ATC code: A10A) or other 
glucose lowering drugs (ATC code: A10B).   
• Persons who are solely registered in the Danish National Patient Registry with one 
specific ICD-code for type 2 diabetes (ICD-10 code: E11).  
• Women who have solely claimed a prescription of Metformin (ATC code: 
A10BA02) and have a claimed prescription of Clomiphene (ATC code: G03GB02) 
or an Antiandrogen combined with Oestrogen (ATC code: G03HB) or have a 
diagnosis of polycystic ovarian syndrome (ICD-10 code: E282) in the Danish 
National Patient Registry.   
• Persons who are not registered in the Danish National Prescription Registry with a 
claimed prescription of insulin or insulin analogues (ATC code: A10A) or other 
 
 
 
glucose lowering drugs (ATC code: A10B) or who does not have a relevant 
diagnosis in the Danish National Patient Registry 10 years from their index date.   
  
Algorithm for identification of Type 1 diabetes  
Inclusion:  
• Persons with a minimum of one claimed prescription of insulin or insulin analogues 
(ATC code: A10A) in the Danish National Prescription Registry. 
• Persons with relevant primary or secondary diagnosis (ICD-10 code: E10) as the last 
diagnose of specific diagnoses (ICD-10 code: E10 and E11) in the Danish National 
Patient Registry. 
  
Exclusion: 
• Persons who are solely registered in the Danish National Prescription Registry with 
one prescription of insulin or insulin analogues.  
• Persons who are solely registered in the Danish National Patient Registry without a 
claimed prescription of insulin or insulin analogues (ATC code: A10A).  
• Persons classified as type 2 diabetes patients according to the algorithm for 
identification of type 2 diabetes.  
• Women with a diagnosis of gestational diabetes (ICD-10 code: 024.4) in the Danish 
National Patient Registry, who solely have a claimed a prescription of glucose 
lowering drugs in the Danish National Prescription Registry within 280 days before 
first contact or 280 days after last contact with gestational diabetes.  
• Persons who are not registered in the Danish National Prescription Registry with a 
claimed prescription of insulin or insulin analogues (ATC code: A10A) 10 years 
from their index date.
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